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CHAPTER 1 – INTRODUCTION

1.1 Histone Deacetylase (HDAC) Proteins
1.1.1 Chromatin Structure and Epigenetics
When Watson and Crick first described the double helical structure of
deoxynucleic acid (DNA),1 it was only the beginning of the scientific communityʼs
understanding of the complex structure of DNA and chromatin, and the
mechanisms involved in gene expression in eukaryotes. Although chromosomes
were known to package DNA in the nucleus, it wasnʼt until the late 1970ʼs that the
role of histone proteins was revealed by Kornberg, who further described the
structure of chromosomes as double stranded DNA organized around a octamer
of histone proteins to form the nucleosome.2

The crystal structure of the

nucleosome published by Luger et al. in 1997 revealed the octamer of histone
proteins with accessible lysine-rich tails protruding from the nucleosomal core
and in close proximity to the double stranded DNA coiled (Figure 1.1).3,4 The
nucleosome structure consists of pairs of histone proteins H2A, H2B, H3 and H4
associated with 146 base pairs of DNA (Figure 1.1).3 The nucleosomes are
linked together by a varying length of DNA associated with H1 histone proteins in
repeating units, which together coil to form the larger structure of chromatin
fiber.4

These nucleosomal structures are critical for organization of the vast

amount of DNA into the compact structure of the chromatin in the nucleus of
eukaryotic organisms (Figure 1.2).
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Figure 2. X-Ray Structure of Nucleosome Core Particle

Figure
1.1. Crystal Structure of the Nucleosome. Four pairs of histone
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H2B,Three
H3helices
and from
H4)theform
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of the
146 in this view at the upper left.
The unstructured histone tails, absent from the X-ray structure, are drawn as dashed lines of appropriate length, with lollipops to indicate
base
pairs of double stranded DNA wrapped around the histone core.
acetylation sites. H2A tails are both N terminal (bottom) and C terminal (top), while tails shown for the other histones are all N terminal.
3
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translational modifications to both histone proteins and methylation directly to the
DNA bases (Figure 1.2).6 Post-translational modifications that are inheritable
through mitosis, affecting the expression of genetic material without altering the
DNA sequence, are known as epigenetic modifications.6

While the field of

genomics studies the DNA sequence, a new field of epigenomics has emerged to
study the genome-wide chromatin modifications that direct gene expression in a
given cell type.6 Altered epigenetic patterns during development are responsible
for cell and tissue differentiation; importantly, the epigenome is responsive to
external stimuli and is altered in disease states, like cancer6. The lysine-rich Nterminal tails of histone are subject to a variety of post-translational modification
including methylation, phosphorylation, acetylation, ubiquitination (Figure 1.3),7
sumoylation, and citrullination.8

The reversible acetylation of these lysine

residues will be discussed in further detail in section 1.1.2.

1.1.2 Histone Acetylation and Deacetylation
The acetylation state of N-terminal lysine residues on histone proteins can
play a role in both temporal gene regulation, and also can lead to an altered
epigenetic state.9 In particular, the acetylation state of the lysine tails of histones
affects electrostatic interactions between histone proteins and the anionic
phosphate backbone of the DNA.10

Histone acetylation is promoted by the

histone acetyl transferase (HAT) proteins resulting in a neutral DNA structure
(euchromatin), which is accessible to transcriptional machinery (Figure 1.4).
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Epigenomic Marks. The epigenome can mark DNA in two ways, both of which play a role in turning genes off or on. The first occurs when certain chemical tags called
methyl groups attach to the backbone of a DNA molecule. The second occurs when a variety of chemical tags attach to the tails of histones, which are spool-like proteins
that package DNA neatly into chromosomes. This action affects how tightly DNA is wound around the histones.

Figure 1.2. DNA Packaging Into the Chromosome. The double
stranded DNA (purple) is packed into the complex structure of the
chromosome through interactions with histone proteins (teal). Epigenetic
modifications such as methylation directly on the DNA backbone (black
and white) and chemical tags (yellow pentagons) on the histone tails affect
the structure of the chromosome and the accessibility of specific genes to
transcription factors. When the DNA forms tight interactions with histone
complexes, genes (pink) are not accessible (heterochromatin), while the
open structure of the DNA allows accessibility of genes (euchromatin).
This illustration was obtained courtesy of National Human Genome
Research Institute (NHGRI) (www.genome.gov).
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Figure 1.3. Illustration of Common Modifications to Histone Proteins.
Schematic representing the nucleosome core with common posttranslantional histone modifications including: acetyl lysine (acK), methyl
arginine (meR), methyl lysine (meK), phosphoserine (PS), and
ubiquitinated lysine (uK). Post-translational modifications are represented
by colored shapes (legend in bottom left corner). Figure reproduced with
permission.7
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Deacetylation is performed by the Histone Deacetylase (HDAC) family of proteins
and results in a closed DNA structure; the cationic lysine tails interact tightly with
the anionic phosphate backbone of DNA promoting heterochromatin structure
(Figure 1.4).

Gene repression and altered cell cycle regulation caused by

overactive HDACs has been linked to the proliferation of cancer, and HDACs
have been identified as a drug-target for cancer therapy.11 HDAC proteins and
their inhibitors are the focus of this study.
O
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Figure 1.4. Acetylation/Deacetylation of Lysine Residues. Histone
acetyl transferase (HAT) enzymes with the co-factor, acetyl-CoA, promote
acetylation of lysine residues, resulting in a neutral acetyl-lysine and
euchromatin structure. Acetylation is a reversible modification, and
deacetylation is promoted by HDAC proteins. The anionic lysine residue
can form a tight electrostatic interaction with the anionic phosphate
backbone on the DNA, resulting in heterochromatin.

1.1.3 HDAC Family
In humans, the HDAC family of proteins is comprised of 18 members,
divided into four classes by evolutionary similarities.

Class III HDACs are

comprised of a group of sirtuin proteins that are homologous to the yeast SIR2
HDACs and rely on a NAD+ mechanism that is distinct from the other HDAC
proteins; this class of HDACs will not be discussed any further in this dissertation

7
because they are insensitive to the HDAC inhibitors that are the focus of our
study. The class I, II and IV human HDAC proteins share a highly conserved
metal-dependent active site for efficient acetyl-lysine binding. Class I HDAC
proteins are comprised of HDAC1, HDAC 2, HDAC 3, HDAC 8 and are
homologous to yeast protein Rpd3.

The members of class I share a high

sequence similarity and have a single active site for deacetylation.

These

proteins are localized to the nucleus due to their role in cell cycle regulation,12-14
making them prominent targets for cancer treatment. Class II HDACs are
generally higher in molecular weight than the class I HDACs and are homologous
to yeast Hda1, which is involved in metabolism.12 This class is further divided
into two subclasses: class IIa is comprised of HDAC 4, HDAC 5, HDAC 7, and
HDAC 9, which, like Class I, have only a single catalytic domain; class IIb
contains only HDAC 6 and HDAC 10, which both contain a second active site
(although the second site is only active in HDAC 6). Unlike Class I HDACs,
which remain in the nucleus, most Class II HDACs are able to shuttle from the
nucleus to the cytoplasm where they are involved in metabolic processes.15
Contrary to Class I HDACs, which are expressed ubiquitously in various cell
types, Class II HDACs have different expression in various tissues and may be
involved in differentiation of specific cell types.15 The final class of HDACs, class
IV, is comprised of only HDAC 11, which resides in the nucleus and has only a
single active site; HDAC 11 is thought to have diverged from the other HDAC
proteins early in evolution. The 11 HDAC enzymes in Classes I, II and IV all

8
have a highly conserved metal dependent active site (section 1.1.4), resulting
nonspecific binding to most HDAC inhibitors (section 1.2.2).11,16

1.1.4 HDAC Active Site and Biochemical Function
The catalytic pocket of HDAC family of proteins is highly conserved across
many species. There has been limited crystallographic data for human HDAC
enzymes to offer insight into the structure of the catalytic domain. The crystal
structure of class I enzyme, HDAC8, has been solved, but differs significantly
from other class I enzymes, in that it contains an enlarged binding pocket that
includes potassium or sodium ions.17 Recently, crystal structures of the catalytic
domains of enzymes HDAC4 and HDAC7 have been reported, providing insight
into the class IIa binding sites.18,19

Until recently, when an HDAC2 crystal

structure was solved,20 the crystal structure of HDAC class I bacterial homolog,
histone deacetylase-like protein (HDLP), served as a guide to the likely structure
of class I HDAC binding pocket.21
HDLP is found in the hyperthermophilic bacterium Aquifex aeolicus, and
shares 35.2% sequence identity with human HDAC1. While the native function
of HDLP is unknown, it has deactelyase function towards histones in vitro at
7.5% the rate of purified HDAC1-FLAG.21 In addition, the residues around the
zinc atom in HDLP are completely conserved in human HDAC1, allowing for
computational homology models of human HDAC1.22 The basic features of the
HDLP binding pocket are displayed in the crystal structure bound to HDAC

9
inhibitor, trichostatin (TSA) resolved to 2.1 Å (Figure 1.5).21 The active site is
comprised of a narrow hydrophobic 11Å channel that accommodates the
aliphatic chain linker of TSA (a common feature of HDAC inhibitors) while the
hydroxamic acid binds to the catalytic zinc atom at the bottom of the binding
pocket. The HDLP binding pocket also has a 14 Å cavity that is believed to
shuttle in water for catalysis and shuttle out the acetate released during
deacetylation.22 In addition, the capping group of TSA is shown interacting with
surface residues at the opening of the binding pocket (will be discussed in the
context of HDAC inhibitor SAHA in section 2.2.1) (Figure 1.5).

Figure 1.5. Crystal Structure of TSA in HDLP Binding Pocket.21
Space filling model showing crystal structure of HDAC inhibitor, TSA,
bound to HDLP active site resolved to 2.1 Å. Structural features of HDLP
active site include an 11 Å channel that binds to aliphatic carbon chains,
the catalytically important Zn2+ ion at the bottom of the binding pocket, and
a 14 Å cavity (see text in section 1.1.4 for more detail). Figure reproduced
with permission.21
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A commonly accepted catalytic mechanism for deacetylation of lysine
residues has been postulated based on the key residues HDLP crystal structure
resolved to 1.8 Å (Figure 1.6).21 In this mechanism, the ketone of acetyl lysine
coordinates to the Zn2+ atom, activating the ketone for nucleophilic attack by a
water atom also coordinated to the Zn2+; the water is activated for deprotonation
by H131 (H140 in HDAC1) through hydrogen bonding (Figure 1.6 A).

The

resulting hemiketal is in position to hydrogen bond with neighboring tyrosine
residue (Y297; homologous to Y303 in human HDAC1) (Figure 1.6 B); this
tyrosine is substituted by histidine in Class IIa proteins and results in severely
decreased deacetylation efficiency.18,19,23 The acetate ketone reforms releasing
lysine, which is protonated by catalytically important histidine residue (H132;
homologous to H141 in human HDAC1) (Figure 1.6 B and C). This mechanism
is generally accepted for the different HDAC homologs, despite different
biological functions of individual proteins.

Further characterization of the

functions of different isoforms will be discussed from a genetic approach (section
1.1.5) and from a chemical approach (section 1.2).

1.1.5 Genetic Characterization of Individual HDAC Function and Cancer
The characterization of individual isoform functions of human HDAC
proteins has been largely limited to genetic methods; early genetic profiling of
HDAC activity using HDAC inhibitors TSA, SAHA, and MS-275 (Figure 1.7)
indicated that HDACs play a roll in cell cycle progression and cancer.24
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A

B

C

Figure 1.6. Proposed Mechanism for Lysine Deacetylation by HDAC
Proteins.21 Mechanism for deactylation based on crystal structure of
HDLP protein with catalytically important amino acid residues indicated
(corresponding human HDAC1 residues indicated in brackets). A) The
ketone of acetyl lysine residue coordinates to the Zn2+ atom, activating it
for nucleophilic attack by a water atom also coordinated to the Zn2+ atom.
B) The resulting hemiketal forms hydrogen bonds with tyrosine Y297, in
position to reform of the acetate ketone and release lysine; the lysine is
protonated by catalytically important histidine residue, H132. C) Lysine
and acetate ion are released after catalysis.21 Figure reproduced with
permission.21
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Unfortunately this study could not pinpoint which HDACs are important in cancer
due to the lack of isoform selectivity of HDAC inhibitors24 (see section 1.2.2 for
discussion on HDAC inhibitors).

However, over the past decade genetic

methods have provided some insight into the function of individual HDAC
isoforms and revealed which HDACs are likely related to cancer proliferation.
Early studies into Class I HDAC function included HDAC1 knockout mice,
which were embryonic lethal, but demonstrated altered cell growth indicating a
link to cell proliferation.25 Studies of HDAC1, 2 and 3 using small interfering
ribonucleic acids (siRNA) indicate that these isoforms affect cell morphology and
cell viability, confirming the role of Class I HDAC proteins in cell cycle
regulation.26-28 More thorough studies combining siRNA techniques with cDNA
microarray screening indicate that HDAC1 alone is able to alter expression of
genes related to cell growth and apoptosis.29 In addition, microarray screening
has revealed class I HDAC overexpression in some cancer cell lines including
ovarian (HDAC1-3),30 gastric (HDAC2),31 and lung cancers (HDAC1 and 3).32
Conversely, the physiological role of class IIa HDAC enzymes has been
studied using mice knockout experiments implicating both HDAC5 and HDAC 9
in cardiac development and regulation of cardiac signals;33 similarly, the role of
HDAC4 in skeletogenesis has been revealed through knockout mice studies.34
Studies using knockout mice for the final class IIa enzyme, HDAC7, were
embryonic lethal, but revealed the role of HDAC7 in vascular integretiy.35 Of the
class II enzymes, only HDAC6 (class IIb) overexpression has been observed
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through microarray profiling of cancer cells lines (increased in certain breast
cancers).36
Recent improvements in genetic technology have allowed for the
identification of HDACs 1-3 and 6 as important in progression of certain types of
cancers. These methods unfortunately suffer from lack of direct temporal control
that is only possible using small molecule inhibitors.

Conversely, chemical

genetics have been used as a key strategy towards uncovering the role and
function of HDAC proteins and will be the central focus of this study (see section
1.2 below).

1.2 HDAC Inhibitors and Chemical Genetics
1.2.1 Introduction to Chemical Genetics
Over the past two decades, chemical genetics has emerged as an
important tool to study biological systems through small molecule interactions
with biomolecules.37

Chemical genetics offers temporal control over protein

functionality, providing an understanding of short-term effects of protein function
compared to the long-term effects of eliminating gene products offered by
classical genetics; chemical genetics can serve as a compliment to traditional
genetic methods or supplement when genetic methods are not appropriate.37
The term chemical genetics was first coined by Stuart Schreiber, who was a
pioneer in the field, exploiting natural products and natural product-like molecules
to study proteins and their function.37,38
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1.2.2 HDAC Inhibitors and Chemical Genetics
In his early work in chemical genetics, Schreiber was interested in
studying the natural product trapoxin (Figure 1.7), which induced morphological
changes in mammalian cells. Through the synthesis of trapoxin linked to a solid
phase resin (termed K-trap), the Schreiber laboratory was able to isolate a novel
receptor for trapoxin, which was later termed HDAC1.11,13,24 Trapoxin, like many
of the known HDAC inhibitors (Figure 1.7), is relatively non-selective towards the
11 metal-dependent HDAC isoforms.

To date there has been limited

identification of class selective HDAC inhibitors, and only few HDAC639,40 and
HDAC8 selective inhibitors are known.41
Other non-selective HDAC inhibitors (Figure 1.7) have played an important
role in defining the function of HDAC proteins in cancer. Specifically, HDAC
inhibitor trichostatin (TSA) induced G1 phase cell cycle arrest and morphological
changes in human carcinoma cell lines.42,43 TSA and TSA analogs have also
stimulated terminal cell differentiation in multiple murine leukemic cell lines.44,45
The role of HDACs in apoptosis has been further demonstrated in lymphoid,
colorectal, and neuronal cancer cell lines through TSA-induced activation of
caspase-3 protease, an effector of cell death.46,47 Similarly, HDAC inhibitors have
decreased tumor growth in multiple murine models for human cancers including
mouth, lung, breast, pancreatic, stomach, ovarian, and prostate.48-50
The specific mechanism of HDAC proteins in cancer has been determined
from gene profiling studies using HDAC inhibitors, pointing to genes that are
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affected by aberrant HDAC expression in cancer.11,24 HDAC inhibitors induce
cyclic-dependent kinase inhibitors p21 and p27, which are known to play a role in
regulated cell cycle progression.

Other genes induced by HDAC inhibitors

include Fas, FasL, DR-5 and TRAIL death domains, which signal apoptosis. In
addition to apoptosis, HDAC inhibitors have been associated with mitotic,
autophagic and oxidative cell death, further expanding the likely action of HDAC
inhibitors against cancer cells.11
The relationship between HDAC proteins, gene regulation and cancer
proliferation makes them good targets for cancer treatment,11 and several HDAC
inhibitors are currently in clinical trials for the treatment of cancer.51-53

Two

HDAC inhibitors have been FDA approved for cancer treatment: suberoyl anilide
hydroxamic acid (SAHA, Vorinostat, Zolinza) (Figure 1.7),54 and recently FK228
(romidepsin, Istodax) (Figure 1.7), have been approved for treatment of
advanced cutaneous T-cell lymphoma.55
While non-selective HDAC inhibitors have played an essential part in
elucidating the role of HDAC proteins in cancer and show promise as cancer
therapeutics, selective HDAC inhibitors have the potential to improve both of
these avenues. First, selective inhibitors would allow in vivo studies to determine
the specific function individual HDAC proteins, which has been difficult using
traditional cell biology methods (section 1.1.5).

Second, selective HDAC

inhibitors have the potential to be better drugs with fewer side-effects by targeting
only the HDACs directly involved in the propagation of specific cancers types. A
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substantial limitation towards the identification of selective HDAC inhibitors is the
lack of screening methods against individual HDAC isoforms.

1.2.3 HDAC Inhibitor Screening
Finding selective inhibitors for HDAC isoforms requires effective screens
to probe the binding interaction. Current methods of screening HDAC inhibitors
involve a commercially available in vitro fluorescence screening assay from
Biomol International® using a fluorescently labeled HDAC substrate.56,57 One
serious limitation of the assay is the reliance on recombinant HDAC expressed in
baclovirus or mammalian cells, which is intrinsically low yielding, and very costly
to purchase. Alternatively, the source of HDAC activity is cellular lysates, which
contain almost all of the 11 HDACs, making lysates inappropriate for a selectivity
assay. In addition, the labeled substrate used in this assay may not indicate the
true deacetylation activity against native substrates in vivo. A more desirable
way to monitor the interaction would be using a high throughput assay that would
avoid use of recombinant HDACs.

In addition, an in cellulo assay would

simultaneously screen for cell-permeability.

Alternatively, using antibody

isolation of individual HDAC isoforms from cellular lysates would also provide
access to individual HDAC isoforms for selectivity screening.
The goal of my project is to develop a screening method to evaluate
HDAC inhibitors against individual HDAC isoforms. Our strategy involves using a
bifunctional chemical probe that will bind to HDAC proteins, resulting in a
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measurable signal.

The chemical probes are termed chemical inducers of

dimerization (CIDs) for their utility in dimerizing proteins.37 The development of
CIDs and their utility in chemical genetics will be discussed below (section 1.2.4).

1.2.4 Introduction to Chemical Inducers of Dimerization (CIDs)
A common tool used in chemical genetics are bifunctional small
molecules, used to promote interactions between proteins that would not interact
under native conditions.

These bifunctional small molecules, or chemical

inducers of dimerization (CIDs), are small molecules developed to bind two
proteins simultaneously, causing protein dimerization.58 The utility of CIDs to
influence biological systems was first introduced by the Schreiber and Crabtree
labs when they used a homodimer of the small molecule FK506 (termed FK1012)
to promote oligimerization of FKBP chimeric proteins leading to signal
transduction in the mammalian cells (Figure 1.8).59 Schreiber took advantage of
a well-studied signaling pathway that is activated by extracellular aggregation of
receptors mediated by ligand binding, leading to transphosphorylation of the
intracellular components of the receptors and resulting signaling cascade. By
modifying the receptor system to exclude the extracellular domain and include
three FKBP proteins on the intracellular domain, the signaling could be restored
through aggregations mediated by the FK1012 CID (Figure 1.8). Through this
work, Schreiber and Crabtree demonstrated that synthetic small molecules could
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be used to influence cellular events within mammalian cells, and opened up a
new avenue of chemical genetics for studying biological pathways.

Figure 1.8. Dimerization of Chimeric FKBP12 Through FK1012 CID
Causes Phosphorylation Signaling Cascade. Chimeric proteins
containing 3 FKBP12 domains are localized to the cellular membrane
through myristalation of c-Src amino terminal domain, linked through the ζ
chain of T cell antigen receptor (TCR) complex. Presence of the FK1012
CID causes aggregation of the chimeric proteins, which leads to a
phosphorylation signaling cascade induced by transphophorylation of the ζ
chain of TCR complex59. Abbreviations: phospholipase Cγ1 (PLCγ1);
diacetyl glycerol (DAG); protein kinase C (PKC); MAP kinase (MAPK);
nuclear factor of activated T-cells, nuclear and cellular components
(NFATc,n). Figure reproduced with permission59.
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Since their initial conception, CIDs have been used for a variety of
applications by promoting non-native biomolecule interactions with both
homobifunctional and heterobifunctional CIDs.37,58,60 One of the most common
uses of CIDs has been induction of gene transcription in the three hybrid system,
which has been developed in mammalian cells,61 yeast,62-70 and bacteria;71 the
yeast three-hybrid (Y3H) system and its applications will be discussed in detail in
section 1.3.

CIDs and chemical tools have also been used for biochemical

studies in vitro and some relevant examples will be discussed in section 1.4.
Some novel applications of CIDs that were first developed in vitro, and expanded
to in vivo studies are discussed below.
One of the early applications of CIDs, was in mediating protein
degradation

through

cellular

recruitment

to

a

ubiquitination

complex.

Ubiquitination is a conserved motif for intracellular proteolysis of that is part of
regulated cellular function. The Sakamoto group developed several generations
of CIDs capable of binding to an E3 ubiquitin-protein ligase complex (specifically
the Skp1-Cullin-F box (SCF) complex) that promotes polyubiquitination of the
protein IκBα.72-74 Ubiquitination is mediated by IκBα binding to F box protein βTrCP, through a 10 amino acid phosphopeptide.

CIDs containing the IκBα

phosphopeptide and a ligand for a specific protein target were effective in
causing degradation of the target protein (Figure 1.9); these CIDs were termed
proteolysis targeting chimeric molecules (Protacs).

This method provides a

powerful tool for small-molecule induced knockouts, especially in cases where
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genetic knockouts are unsuccessful.58 The Protac system has been extended to
other applications notably, targeted proteolysis of cancer-promoting proteins in
models.74

Figure 1.9. Schematic Representation of the Protac System for
Targeted Proteolysis. The Protac-1 CID (teal rhomboid linked to a circle)
recruits target protein to the E3 Skp1-Cullin-F box (SCF) complex. In the
proximity of the SCF complex, the target protein is modified with ubiquitin
(Ub) and targeted for degradation by the 26S proteasome. Abbreviation:
hrt1 (H). Figure reproduced with permission.58

Recent advances in CID design has led to the development of CIDs that
can promote an immunogenic response through antibody recruitment targeted to
a specific cell type. The Kiessling laboratory has designed a CID capable of
recruiting anti-Gal antibodies through an α-Gal epitope; the CID was also
designed to bind to ανβ3 integrin receptors that are upregulated in tumorigenesis,
through the short arginine-glycine-aspartic acid (RGD) peptide (Figure 1.10).
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Using this method, the RGD-α-Gal CID was able to bind MCF2 tumor cells and
recruit antibodies from human serum, demonstrating the potential to exploit the
immune system by using bifunctional antitumor therapeutics (Figure 1.10).75
CIDs have proven to be a powerful tool for chemical genetics and show
enormous potential for studying any biomolecule with a known high affinity small
molecule interaction.60 Towards our goal of screening HDAC inhibitors against
an HDACi-based CID, we look towards the yeast three hybrid system (Section
1.3) and an in vitro screening method (section 1.4).
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1.3 Yeast Three-Hybrid (Y3H) System
1.3.1 Introduction to the Yeast Three-Hybrid System
In order to screen small molecule inhibitors of HDAC, the interaction
between HDAC and HDAC inhibitor must produce a detectable signal.

One

method of monitoring small molecule-protein interactions in vivo is by using the
yeast three-hybrid system.62

Yeast have been used as a powerful tool in

chemical genetics due to their well-studied genome that shares high genetic
conservation with humans, and their ease of growth and manipulation.60 The
Y3H is an extension of the yeast two-hybrid system, which relies on direct
protein-protein interaction in the absence of small molecules.76

In the Y3H

system (Figure 1.11) a CID (or “bait”) promotes interaction between two hybrid
proteins, promoting gene transcription and a detectable signal. One of the hybrid
proteins has a DNA binding domain (DBD) and a ligand binding domain to bind
the CID. The DBD anchors the other two hybrid components to the DNA allowing
for transcription, and has been termed the “hook”.62 The other hybrid protein
(termed the “fish”) has a ligand binding domain for the other part of the CID, and
an activation domain (AD) that recruits the transcriptional machinery thereby
activating expression of the target gene. When both hybrid proteins are
expressed in yeast containing a reporter plasmid, incubation with the CID causes
dimerization, promoting gene transcription and a resulting signal (Figure 1.11).62
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Figure 1.11. The Yeast Three Hybrid System. The three-hybrid system
consists of two hybrid proteins and a CID designed to bind to the two
hybrid proteins. In the presence of CID, the components of the Y3H
interact. The “hook” consists of a ligand-binding protein linked to a DNAbinding domain that interacts with an operator on the DNA containing the
reporter gene, anchoring the components to the DNA. The “fish”
component consists of a second ligand binding protein linked to an
activation domain, which will induce gene expression when in proximity to
the reporter gene. The CID is the “bait” that binds to both of the ligand
binding domains and brings all the components of the system together,
resulting in gene expression and an observable signal.62

The Y3H was first introduced by Licitra and Lui in 1996, who synthesized a
CID composed of the hormone dexamethasone (DEX), and the small molecule
FK506.62 DEX was used as a binding partner for rat glucorticoid receptor (rGR)
linked to the DBD LexA; fusion proteins of the GAL4 activation domain (B42)
were screened from a Jurkat cDNA library (Figure 1.12). The reporter plasmid
used in this system contained lexA operators directing the transcription of the
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lacZ gene encoding for β-galactosidase (β-Gal) enzyme.

A qualitative agar

plate-based assay was used with the β-Gal substrate, 5-bromo-4-chloro-3-indolyl
β-D-galactoside (X-gal), which is cleaved to a visibly blue product in the presence
of β-Gal enzyme. Using this method, Licitra and Lui confirmed two variants of the
FKBP12 protein as binding partners for the FK506-DEX CID.62 Screening using
the Y3H system was achieved in a fraction of the time it would have taken using
purely biochemical methods.62 Significantly, the DEX-FK506 interaction with the
FKBP12-B42 hybrid proteins could be disrupted in the presence of 10-fold
excess of FK506, indicating that the Y3H may be useful for competitive inhibitor
screening.62

This report set a precedent for the utility of screening small

molecule-protein interactions using the Y3H system.

rGR

DEX

FK506 FKBP12

B42

LexA
B-galactosidase
Plasmid
DNA
LexA binding sites

LacZ reporter

Figure 1.12. Licitra and Luiʼs Y3H.62 Hybrid protein LexA-rGR binds to
the LexA operator of the LacZ reporter plasmid. In the presence of the
DEX-FK506 CID, hybrid protein of FKBP12-B42 is recruited to the DNA,
inducing transcription of β-galactosidase enzyme.
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1.4.1 Cornishʼs Dexamethazone-Methotrexate Y3H
The most well-characterized Y3H to date was developed in the Cornish
laboratory in 2000.63 In this report, they took advantage of the strong interaction
between the small molecule methotrexate (MTX) and the protein dihydrofolate
reductase (DHFR) to provide a strong anchor between the “hook” and the “bait”
in the system (Figure 1.13). This interaction is a suitable anchor for the Y3H
system because the MTX-DHFR interaction has been well characterized,77,78 and
displays picomolar affinity;63 the interaction between MTX and DHFR has since
been exploited in several three-hybrid systems.68,79,80

Cornish used a CID

comprised of MTX linked to DEX to recruit the rGR fused B42 AD.63 The first
report of this system used a similar agar-plate based screening methods for
identifying active Y3H systems, but also included a quantitative method for
screening Y3H systems using the β-Gal substrate ο-nitrophenyl-β-D-galactoside
(ONPG) in liquid culture; the ο-nitrophenol cleavage product can be measured
spectrophotometrically at 420 nm.81 The liquid based assay is advantageous for
high throughput inhibitor screening because it reduces the amount of inhibitor
required by screening in small volumes, and allows quantitative assessment of
CID binding. Cornish also optimized her Y3H to incorporate the cDNA encoding
for LexA-DHFR hybrid protein within the yeast chromosome, which showed more
stable results in the Y3H.63,66,67 Importantly, as in the DEX-FK506 system, the
MTX-DEX CID could be out-competed in the presence of 10 fold excess of MTX,
further evidence that the Y3H may be useful for inhibitor screening.57,60,67
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Figure 1.13. Cornish's Y3H. Hybrid protein LexA-DHFR binds to the
LexA operator of the LacZ reporter plasmid. In the presence of the DEXMTX CID, hybrid protein of rGR-B42 is recruited to the DNA, inducing
transcription of β-galactosidase enzyme.63,66,67

1.4.2 Petersonʼs Estrone-Biotin Y3H
In 2004, Peterson introduced a Y3H based on a CID comprised of an
estrone oxime linked to biotin. This CID promoted the dimerization of a LexA
fused to estrogen receptor (ER) protein and a hybrid Steptavidin(SA)-B42 protein
to activate gene transcription of β-galactosidase (Figure 1.14).64 Similar to a βestradiol-biotin CID-based system that he had introduced earlier,65 the estronebiotin CID offered a synthetically accessible method for preparing CIDs that can
interact with high affinity in the Y3H system.64 Peterson was also able to disrupt
the interaction between estrone-biotin CID and the SA-B42 hybrid protein in the
presence of 10-fold excess of biotin, giving further evidence that competitive
inhibitors can effectively disrupt the Y3H.
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Figure 1.14. Petersonʼs Y3H. Hybrid protein LexA-ERβ binds to the
LexA operator of the LacZ reporter plasmid. In the presence of the
estrone-biotin CID, hybrid protein of SA-B42 is recruited to the DNA,
inducing transcription of β-galactosidase enzyme.64

1.4.3 Competitive Inhibitor Screening Using a Y3H System
There is ample evidence suggesting that the Y3H may be an effective tool
for screening small molecule-protein interactions.62-66,82 While the utility has thus
far been limited to screening cDNA libraries encoding for hybrid proteins linked to
an activation domain, the precedent for disrupting the Y3H by a competitive
inhibitor has been set by many groups.62-64,82 In addition, a similar system in
mammalian cells has been used for screening competitive kinase inhibitors.79
We proposed that competitive HDAC inhibitors could be screened in a similar
manner by disrupting the binding of an HDACi-based CID to a HDAC hybrid
protein, causing a loss of signal. In this way, the presence of a small-moleculeprotein interaction could be easily detected and monitored. Design of an HDACbased Y3H will be discussed in Chapter 2.
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1.5 In vitro Selectivity Screening
Chemical genetics have also been used to study biological systems in
vitro when cellular approaches are not appropriate. Similar to our proposed Y3H
competitive inhibitor screen, CID displacement been used to assess kinase
inhibitor selectivity against various kinase proteins in vitro.83,84

Ambit

Biosciences has developed kinase inhibitor-based CIDs which are linked to biotin
for isolation from cellular lysates with magnetic streptavidin coated beads (Figure
1.15).

For this application, biotin-containing kinase inhibitor CIDs have been

used to assay competitive inhibitors against individual kinases displayed on T-7
bateriophage in E. coli lysates.83,84 Using this method, kinase targets could be
detected when bound to the CID, and amplified using reverse transcriptase
polymerase chain reaction (rtPCR). Importantly, the assay was able to determine
in vitro Kds for competitive inhibitors against individual kinase proteins.83,84
Development of a biotin-based HDAC inhibitor CID for in vitro inhibitor screening
will be discussed further in Chapter 3.
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Figure 1.15. In Vitro Kinase Inhibitor Selectivity Screen. Streptavidin
beads (represented by the semi-circle on the right of each diagram) were
coated with biotin-kinase inhibitor CID (biotin as part of the bead with
kinase inhibitor represented by the red hexagons). The coated beads
were used to isolate T-7 bacteriophages (large blue hexagons) displaying
individual kinase proteins (left panel). In the presence of competitive
kinase inhibitors (green hexagons, middle panel), the isolation of T-7
bacteriophages displaying individual kinase proteins is disrupted; noncompetitive inhibitors fail to disrupt the kinase-bead interaction (right
panel). Figure reproduced with permission.83
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While this specific type of screening method has not been used for
assessing HDAC inhibitors, in vitro approaches to studying HDAC proteins with
HDACi-based probes has been successful in several studies. As discussed in
section 1.2.2, the initial isolation of human HDAC1 was achieved using a small a
covalent HDAC inhibitor (trapoxin) displayed on a solid resin.13 This year, a large
study was published using resin-based non-covalent HDAC inhibitors (SAHA and
govinostat) to isolate megadalton HDAC protein complexes, followed by mass
spectrometric analysis.5

Significantly, the bead-based SAHA and govinostat

probe interactions with HDAC proteins was disrupted in the presence of preincubated competitive HDAC inhibitors (Figure 1.16).5

Using this method,

several HDAC inhibitors were screened for binding affinity towards class I and
class IIb HDAC proteins and their corresponding cellular complexes. From the
mass spectrometric analysis of the proteins isolated by these probes both in the
absence of competitive inhibitors, and in addition of varying concentrations of
competitive HDAC inhibitors, IC50 values were extrapolated (Figure 1.16).5 Using
this method the known HDAC 1-3 selective inhibitor romidepsin85 (FK228; Figure
1.16) was confirmed to have greater affinity towards HDACs 1-3 compared to
HDACs 6, 8 and 10, demonstrating the utility of in vitro screening to identify
HDAC selective inhibitors.5

In this study, HDAC isoforms were not isolated

individually, but the megadalton complex components were verified by
quantitative co-immunoprecipitation.5

This study provides precedence for our
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proposed in vitro competitive inhibitor screen that will be discussed in detail in
Chapter 3.

Figure 1.16. Competitive HDAC Inhibitor Disruption of HDAC Protein
Isolation.
HDAC inhibitors SAHA, BML210, Tacedinaline and
Romidepsin (FK228) IC50 determinations were extrapolated through
competitive disruption of SAHA-based and govinostat-based probes to
HDACs 1-3, 6, 8 and 10. Figure reproduced with permission.5
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CHAPTER 2
DEVELOPMENT OF A HDAC-BASED YEAST THREE HYBRID SYSTEM

2.1 Development of a Y3H for HDAC Inhibitor Screening
2.1.1 Competitive HDAC Inhibitor Screening
Class I HDAC enzymes play an important role in gene regulation, and
inhibitors of this family of proteins have been identified as targets for cancer
therapy. Many of the known HDAC inhibitors are non-selective towards the 11
metal-dependent HDACs and current methods are limited in screening inhibitors
for selectivity against individual HDAC isoforms. A high-throughput screening
method has the potential to significantly improve current methods of identifying
selective HDAC inhibitors (HDACi).
Towards the goal of developing a competitive HDACi screening method,
we sought to develop Y3H systems (section 1.3) centered around hybrid HDAC
proteins interacting with HDACi-based CIDs (specifically SAHA-based CIDs; for
discussion and synthesis see section 2.2). We worked on two systems based on
Petersonʼs Y3H system64 (section 1.3.3): the first was based on a SAHA-Estrone
CID (section 2.1.2; synthesis sections 2.2.2-2.2.3); the second was centered on a
SAHA-Biotin CID (section 2.1.3; synthesis section 2.2.4). The final Y3H that we
sought to develop was centered on a SAHA-MTX CID (section 2.1.4, synthesis
section 2.2.4) based on Cornishʼs Y3H system63,77,78 (section 1.3.2).
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Following the previous work done in the Cornish63,77,78 and Peterson64
laboratories, we developed a general strategy for an HDAC-dependent Y3H
(Figure 2.1). The components of our Y3H include a hybrid protein consisting of
bacterial DNA binding domain, LexA, linked to a protein that will bind to a SAHAbased CID. The SAHA-based CID will also interact with a hybrid HDAC protein
fused the transcriptional activation domain, B42.The three hybrid components will
interact with a reporter plasmid through LexA operators bringing B42 into
proximity of the lacZ gene inducing expression of the β-galactosidase enzyme
(Figure 2.1 A).
The goal of our HDAC-based Y3H system is to screen competitive HDAC
inhibitors by blocking binding interactions between hybrid HDAC proteins and
SAHA-based CIDs, thereby preventing gene expression and signal induction
(Figure 2.1 B).

A major advantage to this method would be that the HDAC

isoforms could be screened individually against HDACi and allow for assessment
of selectivity.

In Figure 2.1 B, the competitive HDACi would disrupt the

interaction between the CID (“bait”) and the hybrid protein containing the
transcriptional activation domain (“fish”).

Our SAHA-estrone and SAHA-MTX

Y3H systems use this strategy, while in our SAHA-biotin system the HDAC is
fused to the DNA-binding domain and competitive inhibitors would disrupt the
hook-bait interaction (section 2.1.3). The positive control used in the Y3H assay
consisted on one hybrid protein of LexA and B42 that simultaneously binds the
DNA through LexA operators and activates transcription of the lacZ gene (Figure
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Figure 2.1. General Scheme of HDAC-Dependent Y3H For
Competitive Inhibitor Screening. A) In the presence of SAHA-based
CID, the components of the Y3H will interact causing gene transcription of
β-galactosidase and a measurable signal. B) In the presence of a
competitive HDACi the interaction between HDAC-B42 hybrid protein and
SAHA-based CID is disrupted, failing to induce gene expression. C)
Positive control for the Y3H relies on a fusion protein of LexA and B42,
which induces gene expression in the presence of reporter plasmid.
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2.1 C).

The specific components of the different systems will be discussed in

greater detail below (sections 2.1.2-2.1.4).

2.1.2 SAHA-Estrone Based Y3H
The first HDAC-dependent Y3H assay was inspired by Petersonʼs Y3H
system64 (section 1.3.3) using a SAHA-estrone CID (for structure and synthesis
see section 2.2.2-2.2.3), in lieu of an estrone-biotin CID, to recruit an HDAC-B42
hybrid protein (Figure 2.2).

Our Y3H were performed in Saccharomyces

cerevisiae strain FY250 (MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63), a
generous gift from Blake Peterson.64,65 The plasmids used in the Y3H systems
were under control of a galactose 1 promoter (Pgal1), meaning that genes for
hybrid proteins and reporter enzymes were only induced in the presence of
galatose-containing media; yeast were grown in the absence of galactose prior to
the assay. The reporter plasmid, pSH18-34 (a gift from Peterson) was used,
which has 8 lexA operators directing transcription of lacZ gene encoding for βgalactosidase enzyme under the control of a GAL1 promoter. Other important
features of this plasmid include URA3 yeast selection and ampicillin resistance
(ampR) in bacteria (2μ origin). The second yeast expression plasmid gifted by
Peterson64,65 was pAM423-LexA ERβ (HIS3, 2μ, Pgal1, ampR), encoding for a
fusion protein of LexA and estrogen receptor β (ERβ) (Figure 2.3) followed by
and ADH termination sequence (AdhT).

The pSA1 T7-SA yeast expression

plasmid, also donated by the Peterson laboratory,65 was used to clone DNA
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encoding for HDAC1-B42 and Rpd3-B42 fusion proteins into EcoRI/XhoI
restriction sites using homologous recombination (for complete details see
experimental section 2.7).

Important features of these HDAC-B42 encoding

plasmids include TRP1 yeast selection, AMP resistance in bacteria, a GAL1
promoter and Adh termination domain (see section 2.7 and Figure 2.9). The
positive control for this system was a one-hybrid LexA-B42 fusion protein from
pSH17-4 yeast expression plasmid (Origene, HIS3, Pgal1, 2μ, ampR). With all the
DNA components for the Y3H in hand, a synthetic strategy for the SAHA-estrone
CID was developed (section 2.2.3-2.2.4).

ER-B Estrone

SAHA

HDAC

B42

LexA
B-galactosidase
Plasmid
DNA
LexA binding sites

LacZ reporter

Figure 2.2. Pflum Lab Y3H based on SAHA-Estrone CID. Hybrid
protein LexA-βER binds to the LexA operator of the LacZ reporter plasmid.
In the presence of the SAHA-estrone CID, hybrid protein of HDAC-B42 is
recruited to the DNA, inducing transcription of β-galactosidase enzyme.
HDAC in this figure could represent yeast HDAC, Rpd3; or human
HDAC1.
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2.1.3 SAHA-Biotin Based Y3H
The Y3H system based on a SAHA-biotin CID (Figure 2.3; for structure
and synthesis see section 2.2.4) was also inspired by Petersonʼs Y3H system
(section 1.3.3) using yeast strains and plasmids that he generously gifted our
lab64,65 (see section 2.1.2 for details). As in the SAHA-estrone based Y3H, the
pSH18-34 reporter plasmid was used to mediate expression of β-glactosidase
under the influence of the three hybrid components (section 2.1.2). In addition
the yeast expression plasmid, pSA1 T7-SA (TRP1, 2μ, Pgal1, AdhT ampR),
encoding for the streptavidin-B42 fusion protein was used to bind the biotin
portion of the SAHA-biotin CID. HDAC1-LexA fusion protein was expressed from
yeast plasmid pNLexA-VP16-HDAC1 (cloned by Mary Kay H. Pflum from
commercially available pNLexA to include human HDAC1-VP16 at the N-terminal
of LexA into EcoRI and NotI restriction sites, unpublished; HIS3, 2μ, Pgal1, AdhT
ampR). Important features of this plasmid include HIS3 yeast selection, and amp
resistance in bacteria. The final component of the Y3H was a SAHA-biotin CID,
which was synthesized using a solid-phase strategy (section 2.2.4).
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Figure 2.3. Pflum Lab Y3H based on SAHA-Biotin CID. Hybrid protein
LexA-HDAC1 binds to the LexA operator of the LacZ reporter plasmid. In
the presence of the SAHA-estrone CID, hybrid protein of SA-B42 is
recruited to the DNA, inducing transcription of β-galactosidase enzyme.

2.1.4 SAHA-MTX Based Y3H
The final HDAC-dependent Y3H assay was designed centered around a
SAHA-MTX CID (for structure and synthesis see section 2.2.5). This system was
based on Cornishʼs Y3H system (section 1.3.2) using Saccharomyces cerevisiae
strain, V760Y (MATα trp1 ura3 6lexAop-LEU2 ade4::Pgal1-LexA-eDHFR(HIS3)
GAL+), that she generously gifted our lab.63,67 The V760Y strain was cloned from
strain EGY48 to interrupt the ADE4 chromosomal gene with cDNA encoding for a
fusion of LexA protein linked to dihydrofolate reductase enzyme from E. coli
(eDHFR) flanked by a GAL1 promoter and ADH termination domain. This yeast
strain was used with reporter plasmid pMW112, also a gift from the Cornish
laboratory,63,67 which has 8 lexA operators directing transcription of lacZ gene
encoding for β-galactosidase enzyme under the control of a GAL1 promoter;
other important features of this plasmid include URA3 yeast selection, and
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kanamycin resistance (kanR) in bacteria.

This Y3H system was used with a

SAHA-MTX CID in separate experiments to recruit either an HDAC1-B42 or an
Rpd3-B42 fusion protein (pSA1 HDAC1-B42; pSA1 Rpd3-B42; for description
see section 2.1.2 and experimental section 2.7). The positive control for this
system was a fusion of LexA-B42 fused to the N-terminal of catalytically inactive
mutant HDAC1(H141A) from plasmid p424 HDAC1(H141A)-LexA (Sujith
Weerasinghe unpublished, TRP1, ampR, GPD promoter, CYC1 terminator).86
The design and synthesis of the SAHA-based CIDs for the Y3H systems are
discussed in section 2.2 below; specifics of the SAHA-MTX CID synthesis is
discussed in section 2.2.5.

DHFR

MTX

SAHA
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B42

LexA
B-galactosidase
Plasmid
DNA
LexA binding sites

LacZ reporter

Figure 2.4. Pflum Lab Y3H based on SAHA-MTX CID. Hybrid protein
LexA-DHFR binds to the LexA operator of the LacZ reporter plasmid. In
the presence of the SAHA-MTX CID, hybrid protein of HDAC-B42 is
recruited to the DNA, inducing transcription of β-galactosidase enzyme.
HDAC in this figure could represent yeast HDAC, Rpd3; or human
HDAC1.
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2.2 SAHA-Based CIDs
2.2.1 Design of SAHA-Based CIDs
To create the HDAC-dependent Y3H systems, we next designed HDACi
CIDs. Our HDACi-based CIDs incorporate the small molecule SAHA (Figures 1.7
and 2.2), which has a synthetically accessible structure and is known to inhibit all
of the HDAC isoforms relatively nonselectively.16,87

Based on the crystal

structure of SAHA binding to a bacterial HDAC homolog HDLP (see section 1.1.4
for discussion of active site), we reasoned that the optimal place to derivatize
SAHA would be on the aromatic ring, which is located in the solvent exposed
region when SAHA binds to the active site of HDAC proteins (Figure 2.5).21,88
Structure activity relationship (SAR) studies of SAHA indicate that substituents
along the linker chain of SAHA near the hydroxamic acid severely decrease
binding affinity towards HDAC proteins,89 while modifications towards the solvent
exposed region (Pflum and Bieliauskas unpublished data), and to the aromatic
ring of HDAC inhibitors can actually increase potency.16,51,90

For our SAHA-

based CIDs, the aromatic ring will be functionalized to display either an amine or
carboxylic acid that will be connected through a linker and to the second small
molecule of the CID.
For the synthesis of SAHA-based CIDs, several different methods were
explored to develop a facile synthesis that could be amended to accommodate
different small molecules attached to SAHA through a linker. A general strategy
was desired where either an amine or carboxylic acid would be displayed on the
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Figure 2.5 Crystal Structure of SAHA in the HDLP Active Site. A)
Structure of SAHA. B) Space filling model of crystal structure of SAHA in
the HDLP binding pocket. Zinc atom is colored purple; oxygen is red;
nitrogen is blue; carbon is yellow. Reproduced with permission.88
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aromatic ring of SAHA, which is positioned in the solvent exposed region as
SAHA binds to the active site of HDAC proteins. Our initial plan for the synthesis
of the SAHA-based CIDs was to employ traditional solution phase synthesis by
successive amide bond coupling reactions (section 2.2.2); this method was used
towards the development of a SAHA-estrone Y3H (section 2.1.2, synthesis
section 2.2.3).

A solid-phase synthesis was then established for the

development of the SAHA-biotin Y3H (section 2.1.3 synthesis section 2.2.4) and
for the SAHA-MTX Y3H (section 2.1.4, synthesis section 2.2.5).

2.2.2 Exploratory Solution-Phase SAHA-Based CID Synthesis
The synthesis of the SAHA fragment of the CID in solution phase was
inspired by a previously reported synthesis of SAHA, in which suberic acid (2)
was converted into the cyclic anhydride 3. In this report, the anilide was installed
by ring opening with aniline, followed by installation of the hydroxamic acid to
afford SAHA (1) (Scheme 2.1).52
Scheme 2.1. Previous SAHA Synthesis.52
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Following the previous method,52 suberic acid 2 was converted into
suberic anhydride 3 in the presence of acetic anhydride (Scheme 2.2). Initially,
aniline derivatives 5a-d with nucleophilic moieties at the para and meta positions
were used to open anhydride 3, but all resulted in products that were highly
insoluble

in

organic

solvents

and

therefore

not

conducive

to

further

transformations (Scheme 2.2).

Scheme 2.2. Exploratory SAHA Analog Synthesis
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As an alternative to the synthetic strategy from the published SAHA
synthesis (Scheme 2.1), the hydroxamate was installed first by opening suberic
anhydride 3 with O-benzyl protected hydroxylamine to provide O-benzyl
protected hydroxamate 8 (Scheme 2.3). The benzyl protection was chosen
because of the ease of deprotection in the presence of palladium on carbon and
hydrogen gas, which would avoid the difficult purification of the hydroxamic acid
by column chromatography. Soluble hydroxamate 8 was then coupled to aniline
derivative 5a in the presence of carbodiimide (CDI) and triethylamine (TEA), but
again yielded an insoluble SAHA derivative, 9 (Scheme 2.3).

To circumvent
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solubility issues associated with the SAHA derivatives, aniline derivatives with
carbon linkers between the aromatic ring of SAHA and the added functional
group were used for future syntheses. As an alternative method, hydroxamate 8
was preactivated in the presence of DIPCDI and N-hydroxy succinimide (NHS),
and then coupled to unprotected 4-aminophenylacetic acid (10) in the presence
of TEA to afford SAHA fragment 11 containing a free carboxylic acid for future
derivatization. With a viable strategy for a solution-phase synthesis of SAHAbased CIDs, a strategy for the synthesis of a SAHA-estrone CID was developed
(section 2.2.3).

Scheme 2.3. Solution-Phase Synthesis of SAHA for CID Synthesis
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2.2.3 Solution-Phase Synthesis of SAHA-Estrone CID
The solution-phase synthesis was designed initially for the creation of a
SAHA-estrone CID inspired by Petersonʼs estrone-biotin CID synthesis (Scheme
2.4) from the Y3H system discussed in section 1.3.3.64 Petersonʼs laboratory
constructed the estrone-biotin CID 18 by first converting commercially available
estrone

12

to

oxime

14

in

the

presence

of

carboxymethoxylamine

hemihydrochloride 13, followed by amide coupling reactions to incorporate the
N,Nʼ-dimethyl-1,6-hexanediamine linker 15 and activated biotin fragment 17 with
a 6-amino caproic acid linker.64
Scheme 2.4. Synthesis of Petersonʼs Estrone-Biotin CID.64
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Based on the previous syntheses of SAHA and estrone, we devised a
retrosynthesis to create a SAHA-estrone CID 19 (Scheme 2.5). In this scheme,
the SAHA fragment 20, with a 6-amino caproic acid linker, would be coupled to
estrone fragment 16, linked through N,Nʼ-dimethyl-1,6-hexanediamine.

The

linker 21 was to be coupled to SAHA fragment 11, which would be synthesized
(following the method in section 2.2.2) from suberic acid (2), O-benzyl
hydroxylamine (7), and aniline derivative 10. Estrone fragment 16 would come
from estrone 12, carboxymethoxylamine hemihydrochloride 13 and diamine linker
15 following Petersonʼs protocol (Scheme 2.4).64
This strategy to create the SAHA-Estrone CID (Scheme 2.6) was based
on the method reported by Peterson.64

First, SAHA fragment 11 was pre-

activated in the presence of DIPCDI and NHS, then coupled to unprotected 6aminocaproic acid (21) in the presence of TEA to afford SAHA fragment 20
(Scheme 2.6). This SAHA fragment was very difficult to purify, and only limited
1

H NMR characterization was obtained; this material was used to attempt the

SAHA-estrone synthesis (below). Following Petersonʼs Protocol, estrone 12 was
converted to oxime 14 in the presence of hydroxylamine 13, and then in a twostep one pot synthesis,64 amine linker 15 was couple to the oxime followed by 20
(Scheme 2.7). Unfortunately, this strategy resulted in a mixture of products that
was difficult to purify from amine and carboxylic acid components. An alternative
solid-phase synthesis was developed towards the synthesis of SAHA-Biotin CIDs
(section 2.2.3) and used to develop a SAHA-MTX CID (section 2.2.4).
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Scheme 2.5. Retrosynthesis of SAHA-Estrone CID.
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Scheme 2.6. Synthesis of SAHA Fragment (20).
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2.2.4 Solid-Phase Synthesis of SAHA-Biotin CIDs.
As an alternative to the solution phase synthesis, a resin-based solid
phase synthesis was developed in order to avoid tedious purification of highly
polar

amine

and

carboxylic

acid

derivatives.

Commercially

available

hydroxylamine Wang resin allowed for creation of the hydroxamate directly on
the bead; forming the hydroxamic acid on the bead served to protect this
sensitive group to be released only in the final step,91 as well as facilitate the
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amide coupling and deprotections used to construct the SAHA-based CIDs. This
method has been used to create hydroxamic acids using hydroxylamine Wang
resin,91-93 including in the synthesis of HDACi-based probes published by the
Cravatt laboratory shortly after we began using this method.94
A retrosynthesis (Scheme 2.8) using the hydroxylamine Wang resin was
devised for the creation of SAHA-biotin CID A (22). In this scheme, biotin 23 and
polyethylene glycol linker 24 would be added to SAHA based bead 25 through
amide coupling reactions.

SAHA bead 25, functionalized with an amine for

coupling reactions, would come from hydroxylamine Wang resin 27, suberic
anhydride 3, and Boc-protected 4-amino benzylamine 26.
Using this method, the aniline derivative 28 was first selectively Boc
protected in high yield, then used to open suberic anhydride to afford derivative
29 (Scheme 2.9).

This suberoyl anilide derivative 29 was then coupled to

hydroxylamine Wang resin 27 to give bead-based SAHA derivative 25, which
was then Boc deprotected in the presence of 20% trifluroacetic acid (TFA) in
dichloromethane (DCM). Polyethylene glycol linker 24 was then added to the
beads, in the presence of diisopropylethylamine (DIPEA) and O-(Benzotriazol-1yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), followed by Fmoc
deprotection in the presence of 20% piperidine in DMF to afford SAHA fragment
30. Finally, biotin (23) was added under similar coupling conditions, followed by
cleavage from the resin using TFA in DCM (1:1)93,95 to give SAHA-biotin CID A
(22) (Scheme 2.9); anhydrous conditions were used during resin cleavage to
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avoid hydrolysis of the hydroxamic acid to the corresponding carboxylic acid.91
The HPLC purification of this compound revealed a mixture of products, and only
a trace amount of 22 was isolated (no yield calculated, Appendix A.13.1). In
addition, HPLC reinjection of this compound revealed degradation to several
different peaks.

Scheme 2.8. Retrosynthesis of SAHA-Biotin CID A (22).
O

O
S

HN

O

N
H

O

N
H

2

N
H

NH
O

O
6

NHOH

SAHA-biotin A (22)

O
S

HN

OH
FmocHN

NH

O

O

H2N

OH

N
H

2

O

O

biotin (23)

24

O
6

N
H

O
Wang
Resin

SAHA bead (25)

H2N

BocHN
NH2

26

O

O

3

O

O
Wang
Resin

27

53
Scheme 2.9. Synthesis of SAHA-Biotin CID A (22).
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This first version of the SAHA-biotin CID A was used in NeutrAvidin pullout
experiments described in Chapter 3 (section 3.2.1, Figure 3.2). Although the
initial experiments were successful, further experiments were limited due to poor
stability of the CID, and HPLC reinjection revealed further decomposition of the
purified CID (Appendix A.13.2).

A decomposition pathway was proposed to

describe the low stability of the SAHA-biotin CID A (Figure 2.6).

The acidic

conditions used to cleave the SAHA-based CIDs from the Wang resin allowed for
a stable amide leaving group, which in combination with resonance from the
anilide into the aromatic ring, provided a likely route for SAHA-biotin CID A (22)
decomposition (Figure 2.6).
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Figure 2.6. Proposed Decomposition Pathway of SAHA-Biotin CID A
(22). In the presence of H+, the anilide amine electron pair could resonate
through the aromatic ring causing elimination of the stable amide leaving
group and resulting in cleavage of SAHA-biotin CID A (22).
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To overcome this instability, while maintaining a similar synthetic route, 4aminophenylethylamine (31) was used in the place of 4-(amino)benzyl amine
(28) to determine if an additional methylene between the amine and the aromatic
ring would eliminate the decomposition pathway. Initially, the SAHA-biotin CID B
(36) was constructed following the same method (Scheme 2.10) as the synthesis
in the original SAHA-biotin CID A (22) in Scheme 2.9. Using the alternative
aniline derivative, SAHA was constructed on the bead first by Boc protecting 4aminophenylethylamine 31 in high yield, followed by opening suberic anhydride 3
to produce aniline 33, which was then coupled to the hydroxylamine Wang resin
27 in the presence of DIPEA and TBTU (Scheme 2.10). Once the Boc group
was deprotected in the presence of 20% TFA in DCM, polyethylene glycol linker
24 was then coupled to the beads, followed by Fmoc deprotection in the
presence of 20% piperidine in DMF. Finally, biotin (23) was added under similar
coupling conditions before the CID was cleaved from the bead in the presence of
TFA and DCM (1:1) to afford SAHA-biotin CID B (36) in 2.8% overall yield over 6
steps.
The new version of the SAHA-biotin CID (36) showed an increase in the
ratio of product to side products present in the HPLC after cleavage from the
Wang resin (Appendix A.14.1). However, the use of the Boc protection on aniline
derivative 32 required a 20% TFA solution for deprotection on the resin, while the
conditions used to cleave the hydroxylamine from the resin were 50% TFA over a
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90 minute period.

The use of the Boc protection, and the cleavage in TFA

potentially lowered the yield of the SAHA-biotin CID B (36).

Scheme 2.10. Initial Bead-Based Synthesis of SAHA-Biotin CID B (36).
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To avoid possible complications associated with using the Boc protecting
group with the Wang resin, an alternate and simplified retrosynthesis for SAHA
bead (34) was devised using an Fmoc protection strategy (Scheme 2.11). In this
scheme, SAHA bead (34) would come from Fmoc protected aniline derivative 37,
suberic acid monomethyl ester 38 and hydroxylamine Wang resin 27 connected
through amide bonds.

Scheme 2.11. Retrosynthesis of Bead-Based SAHA Using Fmoc Protection.
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Using the Fmoc proctected aniline derivative 37 led to a more simplified
bead-based synthesis of SAHA-biotin CID where all amide bonds were
constructed directly on the resin. Prior to the synthesis on the resin, the Fmoc
group was installed on amine 31 using N-(9-Fluorenylmethoxycarbonyloxy)
succinimide (FmocOSu) in dioxane to give Fmoc protected derivative 37. The
FmocOSu was chosen due to its lower reactivity (compared to FmocCl) in order
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to selectively protect the primary amine and avoid side-reactions with the
aromatic amine.

Scheme 2.12. Fmoc Protection of 2-(4-aminophenyl)ethylamine (31)
FmocOSu
dioxane
63%

H2N

FmocHN

NH2

31

NH2

37

For the bead synthesis, first suberic acid monomethyl ester 38 was added
to hydroxylamine Wang resin 27 in the presence of DIPEA and TBTU to
construct the hydroxamate on the resin (Scheme 2.13). The methyl ester was
then hydrolyzed in saturated lithium hydroxide (LiOH) mixed with THF in a
biphasic solution (1:2) for 8 hours.96 The free carboxylic acid of bead 40 was
then coupled to Fmoc protected derivative 37 in the presence of DIPEA and
TBTU, followed by Fmoc deprotection in the presence of 20% piperidine in DMF
to give SAHA fragment 23. The PEG linker and biotin were then added following
the same method used in Scheme 2.10, followed by cleavage from the bead to
give identical SAHA-biotin CID B (36) in 7.7% yield over 8 steps (Scheme 2.13).
The low yield may be due to Fmoc deprotection of aniline 37 during the coupling
to hydroxylamine Wang resin 27; perhaps the yield may be improved if less
DIPEA is used during this step under more dilute coupling conditions.

This

SAHA-biotin CID B (36) was used in the Y3H (results section 2.3) and towards
development of an in vitro assay (Chapter 3).
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Scheme 2.13. Optimized Synthesis of SAHA-Biotin CID B (36)
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2.2.5 Synthesis of SAHA-MTX
Several solid phase synthetic routes towards SAHA-based CID syntheses
were explored in the development of the SAHA-biotin CIDs discussed in section
2.2.4.

For the synthesis of SAHA-MTX the most direct route was used.

A

retrosynthetic strategy was devised (Scheme 2.14) where MTX fragment 42
would be added to the SAHA-based resin in the final step through amide
coupling; the MTX fragment 42 would come from aromatic alcohol 44 and Nmethyl p-amino benzoic acid (N-methyl PABA) 45. The glutamic acid portion of
MTX would be added to the SAHA-based resin 43 through an amide bond to the
side-chain carboxylic acid of glutamate by employing an Fmoc protection on the
amine and tBu protection and the C-terminal carboxylic acid (Fmoc-Glu-OtBu 46)
(Scheme 2.14).

For the synthesis of SAHA-MTX, SAHA bead 45 would be

synthesized using the most direct method following the synthesis outlined in
Scheme 2.13.
With an efficient bead-based synthesis of SAHA-based CIDs in hand, the
MTX fragment 42 was generated following a previous protocol.97

First, 2,4-

Diamino-6-(hydroxymethyl)pteridine hydrochloride 44 was converted in the
presence of triphenyl phosphine dibromide to aryl bromide 47, which then
underwent SN2 reaction with N-methyl PABA 45 to give MTX fragment 42
(Scheme 2.15). Prior to coupling MTX fragment 42 to the bead, Fmoc-Glu-OtBu
46 was coupled to bead 35 and Fmoc deprotected (Scheme 2.9). Once MTX
fragment 42 was linked to SAHA using standard coupling conditions, the CID was
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Scheme 2.14. Retrosynthesis of SAHA-MTX CID.
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cleaved from the resin in 50% TFA/DCM, simultaneously removing the tBu
protection. The SAHA-MTX CID 41 was purified by HPLC in 5.2% yield for
application to the Y3H system (results sections 2.3).

Scheme 2.15. Synthesis of MTX fragment of SAHA-MTX.
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2.3 Three Hybrid Screen Results and Discussion
2.3.1 SAHA-Biotin Y3H
With all the plasmid components and SAHA-biotin CID B (36) in hand, the
yeast three hybrid assay (section 2.2.3) was performed (Figure 2.7). Negative
controls were performed with yeast containing only the reporter plasmid pSH1834 (lanes1 and 4) and positive controls were performed with yeast containing
reporter plasmid and LexA-B42 expression plasmid pSH17-4 (lanes 3 and 6).
The assay was performed in both the absence (lanes 1-3) and presence (lanes
4-6) of SAHA-biotin CID B (36). There was strong activation of β-galactosidase
activity in the positive control of more than 100 fold over the negative control.
There was no activation of β-galactosidase in Y3H system containing all of the
plasmid components (Reporter, HDAC1-LexA and SA-B42) in either the absence
or presence of 36.

The failure for the SAHA-biotin CID to induce gene

expression is likely due to the yeast cell impermeability of SAHA, demonstrated
independently by Sujith Weerasinghe.98 In a similar one-hybrid screen, Sujith was
able to slightly increase the SAHA cell permeability through cell wall degradation
with the lytic enzyme zymolyase. Our Y3H was also performed in the presence
of zymolyase enzyme (Figure 2.7, red bars), but did not have an effect on βgalactosidase activity in the Y3H in the presence of SAHA-biotin CID B (lane 5).
While biotin has been used successfully in Petersonʼs yeast systems,64,65,99 these
results suggest that SAHA is not appropriate for studies in yeast due to cell

64
impermeability. Similar results were obtained in the SAHA-MTX Y3H (section
2.3.2).
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Figure 2.7. Results of the SAHA-Biotin Y3H. Relative β-Galactosidase
activity from ONPG cleavage expressed as (OD420)/[OD600*volume of
culture (0.25 mL)*time (min)]; control lane 1 (-) zymolyase set as 1.
Reporter is pSH18-34; SA-B42 from plasmid pSA1 T7SAB42; HDAC1-Lex
from plasmid pN LexA-HDAC1-VP16; LexA-B42 from plasmid pSH17-4;
assay performed in S. cervisiae strain FY250, for detail see section
2.2.3.64,65,99 Results are the average of two independent trials.

65
2.3.2 SAHA-MTX Y3H
With a viable synthesis of SAHA-MTX CID (41) (section 2.2.5), yeast
expression plasmids for HDAC1-B42 and Rpd3-B42 were created (section 2.7).
With all of the components in hand the SAHA-MTX Y3H assay was performed
(Figure 2.8). Negative controls were performed with yeast containing only the
reporter plasmid pMW112 with LexA-DHFR expression encoded into the
chromosomal DNA67 (lanes1 and 5) and positive controls were performed with
yeast containing reporter plasmid and LexA-B42 (lanes 4 and 8). The assay was
performed in both the absence (lanes 1-4) and presence (lanes 5-8) of SAHAMTX CID (41). There was strong activation of β-galactosidase activity in the
positive control of 25-45 fold over the negative control and no activation of βgalactosidase in Y3H system containing all of the plasmid components (Reporter,
HDAC1-LexA and SA-B42) in either the absence or presence of 41. Similar to
the SAHA-biotin Y3H (section 2.3.1), zymolyase did not increase the activation of
β-galactosidase in the presence of SAHA-MTX with either human HDAC1-B42
AD (lane 7) or with the yeast Rpd-B42 AD (lane 6). MTX had been used in many
Y3H systems,63,66-68,80 giving further evidence that SAHA likely obstructs cell
permeability of the CID, and is not appropriate for the development of a yeast
three-hybrid system.

In addition, MTX has recently been revealed to inhibit

HDAC proteins100, further complicating the development of this assay.
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Figure 2.8. Results of the SAHA-Biotin Y3H Relative β-galactosidase
activity from ONPG cleavage expressed as (OD420)/[OD600*volume of
culture (0.25 mL)*time (min)]; control lane 1 (-) zymolyase set to 1.
Reporter is pMW112; LexA-DHFR integrated into yeast chromosome of S.
cerevisiae strain V760Y; Rpd3-B42 from plasmid pSA1 Rpd3-B42;
HDAC1-B42 from plasmid pSA1 HDAC1-B42; LexA-B42 from plasmid
p424 LexA-HDAC1(H141A)-B42; for detailed description see section
2.2.4. Results are the average of two independent trials.
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2.4 Solution Phase Synthetic Methods
2.4.1 General Chemicals and Characterization
Unless noted otherwise, solvents were purchased from Fisher Scientific,
Mallinckrodt Chemicals or EMD Chemicals and used without further purification;
Tetrahydrofuran

(THF)

was

freshly

distilled

before

use

from

sodium

benzophenone ketyl immediately prior to use; DriSolve® dimethyl formamide
(DMF) was purchased from EMD.

Reagents were generally purchased from

Fisher Scientific, Acros Organics, or Sigma Aldrich. Flash chromatography was
carried out using 60 Å, 230-400 mesh silica gel. NMR spectra were taken on
either a Varian Unity 300 MHz, Varian L900 400 MHz, or a Varian 500 MHz. IR
spectra were taken on a Bruker Tensor 27. HRMS spectra were taken on either
a Waters LCT Premier XE ESI-LC–MS TOF or a Waters GCT EI-TOF. Spectra
are included in Appendix A.

2.4.2 Solution-Phase Syntheses

O

O

O

Suberic Anhydride (3). Acetic anhydride (10.0 mL, 99.3 mmol) was added to a
flame-dried flask containing suberic acid 2 (5.00 g, 28.7 mmol).

The solution

was heated to dissolve the suberic acid, and refluxed for an hour.

The solvent

was then removed under reduced pressure, and the resulting solid was
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recrystallized from acetonitrile to afford 3 as a fine white powder (4.3 g, 96%). 1H
NMR (400 MHz, CDCl3): δ 2.46 (t, 4 H), 1.66 (m, 4 H), 1.39 (m, 4 H);

13

C NMR

(100 MHz, CDCl3): δ 169.8, 35.5, 28.5, 24.0; IR: 2934, 2912, 2872, 2853, 1813,
1742.36, 1702, 1473, 1415, 1381, 1333, 1218, 1195, 1047, 1010, 910, 795, 726,
684 cm-1; HRMS (ESI-LC–MS, m/z); calculated [M+H]+ for C8H13O3 157.0865;
found: 157.0870.

O

H
N

HO

O

O

8-(benzyloxyamino)-8-oxooctanoic

acid

(8).

O-benzyl

hydroxylamine

hydrochloride (1.508g, 9.45mmol) was added to a separatory funnel containing a
solution of sodium carbonate (601 mg, 5.67 mmol) in water (10 mL). The neutral
compound was extracted using ethyl ether (3x10 mL) and dried with magnesium
sulfate. The solution was concentrated in vacuo, and diluted with THF (10 mL).
A solution of suberic anhydride 3 (984 mg, 6.3mmol) in THF (10 mL) was added
dropwise, and the solution was stirred overnight. The product was purified by
flash chromatography (10:9:1, EtOAc/Hex/AcOH) to afford 8 as a white solid
(1.065g, 61% yield).

1

H NMR (500 MHz, CD2Cl2): δ 7.35 (m, 5H), 4.87 (s, 2 H),

2.28 (m, 2H), 2.01 (m, 2H), 1.58 (m, 4H), 1.28 (m, 4H);

13

C NMR (125 MHz,

CD2Cl2): δ 179.1, 129.5, 128.9, 78.4, 34.2, 33.3, 28.9, 27.3, 24.7; IR: 3227, 3033,
2937, 2863, 1694, 1657, 1500, 1255, 1194, 737, 698 cm-1; HRMS (ESI-LC–MS,
m/z); calculated [M+H]+ for C15H22NO4 280.1549; found: 280.1540.

69
HO

O
O

N
H

H
N

O

O

2-(4-(8-(benzyloxyamino)-8-oxooctanamido)phenyl)acetic

acid

(11).

Compound 8 (1.832g, 6.56 mmol) was stirred overnight with DIPCDI (1.1 mL,
7.03 mmol), and N-hydroxyl succinimide (906 mg, 7.87mmol) in 50 mL of
dichloromethane. Activation of the acid was judged by TLC (9:1 DCM/MeOH, Rf
= 0.75). 4-aminophenylacetic acid 10 (2.975g, 19.68mmol) and triethylamine
(7.3 mL, 52.51 mmol) were added to the reaction and stirred for 2 hours. The
reaction was quenched with 1 M aqueous HCl (10 mL) causing an off-white
precipitate to form. The solid was collected and the supernatant was transferred
to a separatory funnel and extracted with EtOAc (3x 30 mL) and dried with
magnesium sulfate. The precipitate was added to the organic extract, and was
dried loaded onto silica gel and purified by flash chromatography (17:2:1,
DCM/acetone/AcOH) to afford 11 as a pale yellow solid (1.631 g, 60%). 1H NMR
(300 MHz, DMSO): δ 12.25 (bs, 1 H), 10.92 (s, 1H), 9.81 (s, 1 H), 7.49 (d, 2H),
7.35 (m, 5H), 7.13 (d, 2H), 4.78 (s, 2 H), 3.45 (s, 2H), 2.25 (t, 2 H), 1.92 (t, 2 H),
1.51 (m, 4 H), 1.24 (m, 4H);

13

C NMR (75 MHz, DMSO): δ 173.9, 171.7, 170.1,

138.6, 136.8, 130.2, 129.4, 129.0. 128.9, 119.8, 77.5, 37.0, 32.9, 29.1, 28.9,
25.7, 25.5; IR: 3277, 3240, 3034, 3007, 2933, 2852, 1656, 1602, 1556, 1413,
1252, 1175, 1021, 981, 814, 732, 697 cm-1; MS (ESI-LC–MS, m/z); calculated
[M+H]+ for C23H29N2O5 413.2, found: 413.2 (M+H)+; calculated [M+Na]+ for
C23H28N2O5Na 435.2, found: 435.2; [M+K]+ for C23H28N2O5K 451.2, found: 451.2;
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[2M+H]+ for C46H57N4O10 825.4, found: 825.5; [2M+Na]+ for C46H56N4O10Na
847.3, found: 847.4; [2M+K]+ for C46H56N4O10K 863.4, found: 863.4.

O
HO

H
N

O
O

N
H

H
N

O

O

SAHA fragment (20). Compound 11 (297 mg, 0.72 mmol) was stirred overnight
with DIPCDI (0.13 mL, 0.792 mmol), and N-hydroxyl succinimide (NHS) (99 mg,
0.864mmol) in 10 mL of dimethylformamide. 6-Aminohexanoic acid 21 (285 mg,
2.16mmol) and triethylamine (0.8 mL, 5.76mmol) were added to the reaction and
stirred for 2 hours. The reaction was quenched with 1 M aqueous HCl (10 mL)
causing a white precipitate to form. The solid was collected and the supernatant
was transferred to a separatory funnel and extracted with EtOAc (3x 30 mL). The
organic layer was then washed 3x20 mL water and 1x20 mL brine to remove any
residual DMF. The precipitate was added to the organic extract, and was dried
loaded onto silica gel and purified by flash chromatography (88:10:2,
DCM/EtOH/TEA) to afford 20 as an off-white solid, and was used without further
purification. See Appendix A.4 for crude 1H NMR (400 MHz, DMSO) spectra.
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O
N

O

OH

HO

Estrone Oxime (14). Estrone 12 (251 mg, 0.93 mmol) was dissolved in pyridine
and stirred overnight with carboxymethoxylamine hemihydrochloride 13 (285 mg,
2.6mmol). Once the reaction was complete as judged by TLC analysis (Rf = 0.3,
CH2Cl2 / CH3OH, 4:1) the reaction mixture was poured into 30 mL of 10%
hydrochloric acid cooled on ice. The product was extracted with EtOAc (3 x 30
mL) and the organic layers were combined and dried with MgSO4. The reaction
mixture was dry-loaded onto silica gel for purification by column chromatography
(DCM/MeOH, 4:1) to give a white powder (310 mg, 97% yield). 1H NMR (400
MHz, CD3OD): δ 7.44 (s, 1H), 7.06 (d, 1H), 6.57 (d, 1H), 6.51 (s, 1H), 4.37 (s,
2H), 4.01 (bs, 1H), 2.78 (t, 2H), 2.55 (t, 2H), 2.29 (d, 1H), 2.17 (t, 1H), 1.97 (d,
1H), 1.88 (m, 2H), 1.44 (m, 6H), 0.89 (s, 3H);

13

C NMR (100 MHz, CD3OD): δ

171.4, 155.7, 137.7, 130.7, 126.7, 115.6, 113.5, 70.6, 53.0, 44.3, 44.1, 38.5,
34.6, 29.7, 27.6, 26.5, 23.2, 17.8; IR: 3362, 3326, 3037, 2968, 2932, 2868, 1686,
1663, 1598, 1522, 1453, 1324, 1287, 1249, 1170, 1085, 1064, 912, 872, 818,
710 cm-1; HRMS (ESI-LC–MS, m/z); calculated [M] for C20H25NO4 343.1784,
found: 343.1788.
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NH2
BocHN

tert-butyl 4-aminobenzylcarbamate (26). Di-tert-butoxycarbonate (5.6 mL, 26.2
mmol) was added slowly to a stirred solution of 4-(amino)benzyl amine 28 (2.8
mL, 24.7 mmol) in THF (20 mL) cooled to 0 °C, and stirred at room temperature
for 2 hours. The solution was then purified by flash chromatography (3:2 ethyl
ether/petroleum ether) to afford 26 as a yellow solid (5.216g, 95.0%).

1

H NMR

(400 MHz, CDCl3): δ 7.06 (d, 2H), 6.62 (d, 2H), 4.78 (bs, 1H), 4.18 (d, 2H), 3.56
(bs, 2H), 1.43 (s, 9H);

13

C NMR (100 MHz, CDCl3): δ 156.1, 145.7, 129.1, 115.5,

79.8, 44.6, 28.7; IR: 3454, 3369, 3223, 3033, 3012, 3000, 2980, 2970, 2876,
1688, 1625, 1518, 1458, 1364, 1247, 1163, 1120, 1027, 931, 865, 822, 787 cm-1;
HRMS (ESI-LC–MS, m/z); calculated [M] for C12H18N2O2 222.1368;

found:

222.1374.

O

H
N
BocHN

OH
O

8-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)amino)-8-oxooctanoic
acid (29). A solution of suberic anhydride 3 (6 mmol, 937 mg) in dichloromethane
(6 mL) was added dropwise to a stirred solution of 26 (6 mmol, 1.334 g) in
dichloromethane (6 mL) cooled to 0 °C, and stirred at room temperature for one
hour.

The solvent was then evaporated under reduced pressure, and the

resulting solid was recrystallized from acetonitrile to give 29 as an off-white
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powder (1.588 g, 70%). 1H NMR (400 MHz, DMSO): δ 11.97 (s, COOH), 9.80 (s,
1H), 7.50, (d, 2H), 7.30 (t, NH, 1H), 6.13 (d, 2H), 4.04 (d, 2H), 2.27 (t, 2H), 2.18
(m, 2H), 1.52 (m, 4H), 1.37 (s, 9H), 1.28 (m, 4H);

13

C NMR (100 MHz, DMSO): δ

175.2, 171.8, 156.4, 138.6, 135.3, 128.0, 119.6, 78.8, 43.7, 37.0, 34.3, 28.9,
25.9, 25.0; IR: 3354, 3321, 3186, 3119, 3040, 2981, 2941, 2852, 1686, 1658,
1597, 1519, 1411, 1367, 1339, 1285, 1253, 1171, 1045, 1028, 968, 929, 865,
837, 784, 724, 691 cm-1; MS (ESI m/z) calculated [M+H]+ for C20H31N2O5 379.22,
found: 379.28; calculated [M+Li]+ for C20H30N2O5Li 385.23, found: 385.32;
calculated [M+Na]+ for C20H30N2O5Na 401.21, found: 401.26; calculated [M+K]+
for C20H30N2O5K 417.18, found: 417.22.

BocHN
NH2

tert-butyl 4-aminophenethylcarbamate (32). Di-tert-butoxycarbonate (3.3 mL,
15.4 mmol) was added slowly to a stirred solution of 4-aminophenylethylamine 31
(2.00 g, 14.7 mmol) in THF (100 mL) cooled to 0 °C. The mixture was stirred
overnight

at

room

temperature.

Solid

yellow

tert-butyl

4-

aminophenethylcarbamate 32 was obtained (3.284 g, 95%) after column
purification (7:1, petroleum ether/ethyl ether). 1H NMR (400 MHz, DMSO): δ 6.80
(d, 2H), 6.45 (d, 2H), 4.82 (s, 2H, NH2), 3.34 (t, NH, 1H), 3.00 (q, 2H), 2.47 (t,
2H), 1.35 (s, 9H);

13

C NMR (100 MHz, DMSO): δ 156.2, 147.4, 129.6, 126.9,

114.6, 78.1, 42.8, 36.2, 29.0; IR: 3362, 3330, 3005, 2980, 2941, 2871, 1711,
1687, 1664, 1520, 1411, 1392, 1366, 1250, 1225, 1171, 1042, 999, 965, 837,
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802, 692 cm-1; MS (ESI m/z) calculated [M+H]+ for C13H21N2O2 237.2, found:
237.4; calculated [M+Li]+ for C13H20N2O2Li 243.2, found: 243.4; calculated
[M+Na]+ for C13H20N2O2Na 259.1, found: 259.4; calculated [M+K]+ for
C13H20N2O2K 275.1, found: 275.3.

BocHN

O
N
H

OH
O

8-((4-(2-((tert-butoxycarbonyl)amino)ethyl)phenyl)amino)-8-oxooctanoic
acid (33).

A solution of suberic anhydride 3 (453 mg, 2.9 mmol) in

dichloromethane (15 mL) was added dropwise to a solution of tert-butyl 4aminophenethylcarbamate 32 (685 mg, 2.9 mmol) in dichloromethane (15 mL)
and stirred overnight. The reaction mixture was then dry-loaded onto silica gel
and purified by flash chromatography starting with 1% triethylamine in
dichloromethane with increasing polarity to 1% triethylamine with 4% methanol in
dichloromethane to 10% methanol then 15% methanol until all the product had
eluted from the column to give 33 as an off-white solid (489 mg, 43.0%). 1H NMR
(400 MHz, DMSO): δ 9.79 (s, 1H), 7.47 (d, 2H), 7.07 (d, 2H), 6.84 (t, 1H), 3.07
(q, 2H), 2.60 (t, 2H), 2.53 (t, 2H), 2.17 (t, 2H), 1.55 (t, 2H), 1.48 (t, 2H), 1.35 (s,
9H), 1.27 (m, 4H);

13

C NMR (100 MHz, DMSO): δ 175.3, 171.7, 138.1, 134.5,

129.4, 119.7, 42.3, 40.2, 38.4, 37.0, 28.9, 25.7, 25.2; IR: 3362, 3329, 3188,
3115, 3035, 2983, 2941, 2870, 1815, 1744, 1683, 1597, 1515, 1468, 1449, 1411,
1367, 1327, 1295, 1248, 1170, 1136, 1041, 998, 967, 871, 838, 801, 691 cm-1;
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MS (ESI m/z) calculated [M+H]+ for C21H33N2O5 393.2389 found: 393.2388;
calculated [M+Na]+ for C21H32N2O5Na 415.2209, found: 415.2212; calculated
[M+K]+ for C21H32N2O5K 431.1948, found: 431.1929.

FmocHN
NH2

(9H-fluoren-9-yl)methyl

4-aminophenethylcarbamate

(37).

N-(9-

Fluorenylmethoxycarbonyloxy)succinimide (4.402 g, 13.05 mmol) was added in
one portion to a solution of 2-(4-aminophenyl)ethylamine 31 (1.615 g, 11.86
mmol) in dioxane (120mL) cooled to 15 °C. The solution was stirred at room
temperature overnight. Water (120 mL) was then added to the reaction and the
solution was neutralized with saturated sodium bicarbonate; the resulting
precipitate was removed by filtration. The aqueous solution was extracted with
dichloromethane (3 x 100 mL). The organic layer was dried with magnesium
sulfate, concentrated and purified by flash chromatography (2% acetone in
dichloromethane) to give 37 as a pale yellow solid (2.675 g, 63%). The final
compound was not exposed to heat while dissolved in column solvent to avoid
self-deprotection of the Fmoc group, and the final compound was rinsed with
ethyl ether to remove any deprotected material. 1H NMR (400 MHz, DMSO): δ
7.91 (s, 2H), 7.71 (d, 2H), 7.44 (t, 2H), 7.35 (m, 3H), 6.87 (d, 2H), 4.89 (s, 2H),
4.32 (d, 2H), 4.24 (d, 1H), 3.16 (q, 2H), 2.56 (t, 2H); 13C NMR (125 MHz, DMSO):
δ 156.7, 147.5, 144.6, 141.4, 129.7, 128.2, 127.7, 126.9, 120.8, 114.7, 65.9,
47.4, 43.1, 35.4; IR: 3449, 3367, 3318, 3063, 3038, 3021, 2971, 2938, 2871,
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2856, 1685, 1621, 1685, 1621, 1583, 1547, 1519, 1466, 1410, 1283, 1256, 1196,
1144, 1100, 1083, 1030, 1006, 936.33, 823, 758, 741, 682 cm-1; MS (ESI m/z)
calculated [M+H]+ for C23H23N2O2 359.2, found: 359.3, calculated [M+Li]+ for
C23H22N2O2Li 365.2, found: 365.3; calculated [M+Na]+ for C23H22N2O2Na 381.2,
found: 381.3; calculated [M+K]+ for C23H22N2O2K 397.1, found: 397.3.

NH2
N

N
H2N

N

Br *iPrOH

N

6-(bromomethyl)pteridine-2,4-diamine (47).

Triphenylphosphine dibromide

(49.676 g, 118 mmol) was stirred in a flask containing N,Nʼ-dimethylacetamide
(DMA) and cooled to near 10 °C. Alcohol 44 (8.178 g, 35.76 mmol) was added in
one portion, and the solution was stirred at room temperature for 3 to 3.5 hours.
The solution was then treated with 2.4 mL of ethanol, added dropwise, and
stirred for 15 minutes. Benzene (380 mL) was then added to the solution, stirred
for 30 minutes, and left at 4 °C overnight during which time a semi-solid formed.
The supernatant was then decanted from the flask, and 195 mL of glacial acetic
acid (heated to 100 °C) was added, stirred to dissolve, and filtered while hot. The
solution was left at room temperature for 4 hours, after which the beige solid that
had formed was collected and washed thoroughly with ethyl ether. The crude
product was then recrystallized from hot isopropanol to give 47 as a brown
crystalline solid (5.539 g, 39.1%).97 1H NMR (400 MHz, DMSO): δ 9.29 (d, 2 H),
9.03 (s, 1H), 8.76 (bs, 1 H), 7.62 (bs, 1H), 4.91 (d, 2H);

13

C NMR (100 MHz,
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DMSO): δ 163.2, 156.5, 151.3, 149.9, 146.3, 123.2, 49.0, 31.5; IR: 3556, 3342,
3126, 2930, 2863, 2785, 2679, 1662, 1555, 1504, 1414, 1363, 1175, 1019, 990,
737, 674 cm-1; MS (ESI-LC–MS, m/z); calculated [M+H]+ for C7H8BrN6 255.0,
found: 255.2; calculated [M+Li]+ for C7H7BrN6Li 261.0, found: 261.3; calculated
[M+Na]+ for C7H7BrN6Na 277.0, found: 277.2; [M+K]+ for C7H7BrN6K 293.0,
found: 293.2.

O
NH2
N
H2 N

MTX fragment (42).

OH
N

N

N

N

Bromide 47 (481mg, 1.06 mmol) and N-methyl-4-

aminobenzoic acid 45 (248 mg, 1.65 mmol) were combined in DMA (1.2 mL).
The mixture was heated to reflux at 55°C for 4 hours. The reaction was cooled to
room temperature and 18 mL of water was added to the reaction. The resulting
precipitate was then collected by filtration, and dissolved in 15 mL of 0.08 M
sodium hydroxide. The solution was filtered through celite and then acidified to
pH 6.5 with dilute hydrochloric acid to give yellow solid 42 (569 mg, 53.7%).97 1H
NMR (400 MHz, DMSO): δ 8.21 (s, 1 H), 8.02 (bs, 1H), 7.77 (bs, 1H), 7.72 (d,
2H), 6.98 (s, 2H), 6.81 (d, 2H), 4.79 (s, 2 H), 3.21 (s, 3H);

13

C NMR (100 MHz,

DMSO): δ 168.1, 163.5, 162.1, 153.8, 152.7, 149.8, 147.8, 132.8, 122.4, 118.3,
112.1, 55.2; IR: 3465, 3361, 3326, 3195, 2941, 1605, 1561, 1524, 1448, 1368,
1248, 1186, 1112, 1001, 949, 920, 828, 776, 701 cm-1; MS (ESI-LC–MS, m/z);
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calculated [M+H]+ for C15H15N7O2 326.14, found: 326.21; calculated [M+Na]+ for
C15H14N7O2Na 348.12, found: 348.23; [M+K]+ for C15H14N7O2K 364.42, found:
364.18.

2.5 Solid-Phase Synthetic Methods
2.5.1 General Methods and Characterization
Tetrahydrofuran (THF, EMD Chemicals) was freshly distilled from sodium
benzophenone ketyl immediately prior to use, or purified by Vacuum
Atmospheres Company solvent purifier; DriSolve® dimethyl formamide (DMF)
was purchased from EMD Chemicals.

Hydroxylamine Wang resin was

purchased from Novabiochem (catalog number 01-64-0454; typically 1.9 mmol/g
resin); 2-[2-(Fmoc-amino)ethoxy]ethoxy}acetic acid linker was purchased from
Peptides International (catalog number FXX-5521-PI);

Fmoc-Glu-OtBu was

purchased from Novabiochem (catalog number 04-12-1075).
All bead reactions were performed in a glass vessel with a fritted disc and a
stopcock to ensure that solvent and reactants could be removed easily and the
resin could be washed effectively. Hydroxylamine Wang resin was soaked in
THF (5 bead volumes) for 45-60 minutes to allow bead swelling prior to
synthesis. Due to the non-polar nature of the polystyrene-based Wang resin,
swelling is maximized in non-polar solvents like THF: most of the reagents that
were used in the coupling reactions are soluble in polar solvents like DMF, and
so a 1:1 mixture of the two solvents was used for all the coupling steps. Coupling
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reactions were performed in the presence of 3 equivalents of reactant, 3
equivalents of TBTU and 6 equivalents of DIPEA. The resin was agitated during
the reactions using a Burrel Model 75 wrist action shaker. Coupling reactions
and deprotections were monitored by the Kaiser reaction unless otherwise noted:
the Kaiser test was performed on a small number of beads that were transferred
to a glass culture tube and washed with ethanol 3 times. To the beads was then
added 2 drops each, of the three following solutions: 1) potassium cyanide (2%
v/v of a 0.1 mM aqueous solution in pyridine); 2) ninhydrin (5% w/v) in ethanol; 3)
phenol (20 % w/v) in ethanol. The small sample of beads was then placed in a
small boiling water bath, and monitored for color change for less than 5 minutes.
A positive test results from ninhydrin reacting with free amines on the beads
indicated by strong blue color, while protected amines result in a negative test
and lack color change. Boc deprotection was achieved in the presence of 20%
TFA in dichloromethane; Fmoc deprotections were performed in the presence of
20% piperidine in DMF.
After each coupling and deprotection step the resin was washed with 10 x
DMF (5 bead volumes) followed by 10 x DMF/THF (1:1; 5 bead volumes). Once
the synthesis was complete, the resin was washed with 10 x DMF (5 bead
volumes) 10 x DMF/THF (1:1; 5 bead volumes), 10 x THF (5 bead volumes),
followed by 10 x ethyl ether (5 bead volumes). The resin was then air-dried and
transferred to a small glass vial, and could be stored in a desiccator at 4 °C. The
SAHA-based CIDs were cleaved from the resin in the presence of TFA (1 mL)
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and DCM (1 mL) with shaking for 1.5 hours93,95. The solution was then filtered
through glass wool stuffed in a Pasteur pipet and rinsed with DCM into a glass
vial. The solution was then frozen and the solvent was removed under reduced
pressure. The final compounds were dissolved in DMSO and diluted 50% with
water and filtered using a 0.45 μm syringe filter (Andwin Scientific catalog
number

NC9132669)

for

high

pressure

liquid

chromatography

(HPLC)

purification.
HPLC was performed on a Waters 1525 binary HPLC pump with
photodiode detector.

SAHA-based CIDs were purified on a semi-preparative

reverse phase C18 column (10 x 250 mm, 5 μ; Grace Altima, catalog number
88063, or Restek Ultra II, catalog number 9604577) with HPLC grade Acetonitrile
and deionized distilled water (0.1% TFA) that was filtered through a 0.45 μm
PVDF filter membrane (Pall catalog number 66480). The HPLC system was
washed with 40 column volumes of 0.05% EDTA solution in a water/methanol
(9:1), followed by 40 column volumes of neutral water to remove residual iron
from the instrument and column.101

The purified SAHA-based CIDs were

collected in “iron-free” glassware treated with 6 M hydrochloric acid overnight,
and rinsed with distilled water. MALDI TOF spectra were taken on a Bruker
Daltronics Ultraflex; HRMS spectra were taken on a Waters LCT Premier XE ESILC–MS TOF. Spectra and HPLC injections can be found in Appendix A.
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2.5.2 Solid-Phase SAHA-Based CID Syntheses
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SAHA-biotin CID A (22). Hydroxylamine Wang resin (2 mmol/g, 100 mg, 0.2
mmol) was presoaked in THF (5 bead volumes, about 3 mL). Once the beads
swelled, the solvent was removed and Boc protected suberoyl anilide 29 (225
mg, 0.6 mmol) and TBTU (193 mg, 0.6 mmol) were added to the vessel as
solids, and THF/DMF solvent system was added to 5 bead volumes. Finally,
DIPEA (0.209 mL, 1.2 mmol) was added, and the beads were shaken overnight.
In later coupling reactions the progress is monitored by the Kaiser test, which
tests positively to free amines, but the hydroxylamine is not sensitive to the test92
and so the beads were left to couple overnight. After at least 16 hours, the beads
were washed (see general methods above). Boc deprotection was achieved in
the presence of 5 bead volumes of 20% trifluroacetic acid (TFA) in
dichloromethane (2 x 5 minutes) and carefully monitored by the Kaiser test. Once
the resin had been successfully deprotected, amide coupling reactions were
performed iteratively first by adding linker 24 (213mg, 0.6 mmol), followed by
biotin 23 (147mg, 0.6 mmol), both in the presence of TBTU (193 mg, 0.6 mmol)
and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5 bead volumes); reactions
times were around 2-3 hours following Scheme 2.9. The final compound (22)
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was obtained after HPLC purification at 3 mL/min (10 x 250 mm, 5 μ; Grace
Altima) with a gradient of H2O (containing 0.1% TFA) to CH3CN of 95:5 to 75:25
over 10 min, followed by gradient to 65:35 over 20 minutes (tR 18.5 min). This
compound was very unstable, resulting in several peaks in the HLPC reinjection
(see Appendix A.13) and only limited characterization was obtained (MALDITOF, data not shown).
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SAHA-Biotin CID B (36).
Method A (Scheme 2.10)
Following the same synthetic method used for synthesis of SAHA-biotin
CID A (22), hydroxylamine Wang resin (1.9 mmol/g, 100 mg, 0.2 mmol) was
coupled to Boc protected suberoyl anilide 33 (253 mg, 0.6 mmol) in the presence
of TBTU (193 mg, 0.6 mmol) and DIPEA (0.209 mL, 1.2 mmol) in THF/DMF (1:1,
5 bead volumes). After at least 16 hours, the beads were washed 10 times with
DMF (5 bead volumes). Boc deprotection was achieved in the presence of 5
bead volumes of 20% trifluroacetic acid (TFA) in dichloromethane (2 x 5 minutes)
and carefully monitored by the Kaiser test. Once the resin had been successfully
deprotected, amide coupling reactions were performed iteratively using 3
equivalents of carboxylate first by adding linker 24 (213mg, 0.6 mmol), followed
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by biotin 23 (147mg, 0.6 mmol), both in the presence of TBTU (193 mg, 0.6
mmol) and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5 bead volumes) with
reactions times around 2-3 hours following Scheme 2.10. The final compound
(36) (3.8 mg, 2.8%) was obtained after HPLC purification at 3 mL/min (10 x 250
mm, 5 μ; Grace Altima, catalog number 88063) with a gradient of H2O
(containing 0.1% TFA) to CH3CN of 95:5 to 75:25 over 10 min, followed by
gradient to 71:19 over 20 minutes (tR 22 min). Characterization of this compound
is listed in Method B (below).

Method B (Scheme 2.13)
Suberic acid monomethyl ester 38 (0.107 mL, 0.6 mmol) was coupled to
hydroxylamine Wang resin (1.9 mmol/g, 105 mg, 0.2 mmol) in the presence of
TBTU (193 mg, 0.6 mmol) and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5
bead volumes). After at least 16 hours, the beads were washed 10 x THF/DMF
(1:1, 5 bead volumes) followed by saponification of the methyl ester in the
presence of saturated lithium hydroxide and THF (1:2, 3 mL total) for 8 hours with
shaking96. After saponification, the beads were washed 10 times with water (5
bead volumes), 10 times with DMF (5 bead volumes), soaked in THF for 30
minutes, and washed 10 x THF/DMF (1:1). Fmoc protected diamine 37 (215 mg,
0.6 mmol) was then coupled to the bead as described above with shaking
overnight in the absence of a Kaiser test, followed by washing.

Fmoc

deprotection was performed in the presence of 20% piperidine in DMF (2 x 10
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min) and monitored by the Kaiser test.

Amide coupling reactions and Fmoc

deprotections were performed iteratively following Scheme 2.13 first by adding
linker 24 (213mg, 0.6 mmol), followed by biotin 23 (147mg, 0.6 mmol), both in the
presence of TBTU (193 mg, 0.6 mmol) and DIPEA (0.20 mL, 1.2 mmol) in
THF/DMF (1:1; 5 bead volumes). The final compound (36) (10.5 mg, 7.7%) was
obtained after HPLC purification at 5 mL/min (10 x 250 mm, 5 μ; Restek Ultra II)
with a gradient of H2O (containing 0.1% TFA) to CH3CN of 95:5 to 78:22 over 10
min, followed by gradient to 77:23 over 20 minutes (tR 16 min). HRMS (ESI-LC–
MS, m/z): [M+H]+ for C32H52N6O8S 679.3489, found: 679.3488.
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SAHA-MTX (41). Following the Method B for the synthesis of SAHA-biotin CID B
(36), hydroxylamine Wang resin (132 mg, 0.2 mmol) was coupled to suberic acid
monomethyl ester 38 (0.107 mL, 0.2 mmol) followed by saponification of the
methyl ester with saturated lithium hydroxide and THF (1:2, 3 mL total) for 8
hours with shaking. After saponification, the beads were washed 10 times with
water (5 bead volumes), 10 times with DMF (5 bead volumes), then soaked in
THF (10 bead volumes) for 30 minutes, and washed with 10 x THF/DMF (5 bead
volumes). Amide coupling reactions and Fmoc deprotections were performed
iteratively following Scheme 2.16.

Fmoc protected diamine 37 (215 mg, 0.6

85
mmol) was then coupled to the bead as described above with shaking overnight
in the absence of a Kaiser test, followed by washing. Fmoc deprotection was
performed in the presence of 20% piperidine in DMF (2 x 10 min) and monitored
by the Kaiser test.

Amide coupling reactions and Fmoc deprotections were

performed iteratively following Scheme 2.13 first by adding linker 27 (213mg, 0.6
mmol), followed by Fmoc-Glu-OtBu (46) (255 mg, 0.6 mmol) and finally MTX
fragment (42) (195mg, 0.6 mmol) in the presence of TBTU (193 mg, 0.6 mmol)
and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5 bead volumes). The final
compound (41) (9.3 mg, 5.2%) was obtained after HPLC purification at 3 mL/min
(10 x 250 mm, 5 μ; Restek Ultra II) with an isocratic system of H2O (containing
0.1% TFA) to CH3CN of 80:20 (tR 22 min). HRMS (ESI-LC–MS, m/z): calculated
[M+H]+ for C42H57N12O10 889.4321, found: 889.4299.

2.6 General Biochemical Methods
2.6.1 General Materials
Reagents were generally purchased from Fisher Scientific, Acros Organics
or Sigma Aldrich unless otherwise noted; complete supplemented media (CSM)
dropout powder was purchased from Bio101 Systems; Yeast Nitrogen Base
without amino acids, BactoTM Agar, BactoTM peptone and Yeast Extract were
purchased from Difco.
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2.6.2 General Equipment
The Pflum lab is equipped with standard biochemical equipment including
centrifuges (Eppendorf models 5415D and 5810R), yeast incubator/shaker
(Barnstead labline MaxQMini 4000), bacterial incubator/shaker (New Brunswick
Scientific C25 Incubator Shaker Classic Series), a Tecan GENios Plus
spectrophotometer, and a FisherBiotech midi horizontal gel electrophoresis
system.

2.6.3 Preparation of Chemocompetent XL1 Blue E. coli
The yeast expression plasmids were replicated in the XL1 blue strain of E.
coli to produce large amounts of plasmid. To enable plasmid transformation into
these cells, they were treated with calcium chloride to induce chemocompetency.
A liquid culture (25 mL) of XL1 blue in LB media (1% peptone, 0.5% yeast
extract, 1% sodium chloride) was grown overnight at 37 °C with shaking at 250
rpm. The following day 4 mL of this culture was seeded into 400 mL of LB
media. The culture was incubated under the same conditions as above until the
absorbance at OD600 was approximately 0.375. The culture was transferred (in
50 mL portions) to pre-chilled 50 mL centrifuge tubes, and cooled on ice for 5-10
minutes. The cells were then collected by centrifugation at 4000 rpm for 10
minutes followed by aspiration of the media. The cells were then washed in 10
mL of cold calcium chloride solution (60 mM CaCl2, 10 mM PIPES, 15% v/v
glycerol). Cells were collected as above, and washed one more time with 10 mL
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of cold calcium chloride solution. Finally, the cells were resuspended in 2 mL of
calcium chloride solution and aliquots (250 µL, approximately 3 transformations)
were stored at -80 °C.

2.6.4 Bacterial Plasmid Transformation
Yeast expression plasmids were transformed into chemocompetent XL1
blues E. coli (section 2.6.3) for plasmid biosynthesis. Plasmid dissolved in water
(1 µL, <0.5 mg/mL) was added to a centrifuge tube containing chemocompetent
cells (70 µL), which were previously thawed on ice. After incubation on ice for 30
minutes, the cells were heat-shocked for 60-90s at 42°C in a heat block and then
placed on ice for 2 minutes. LB media (1 mL) was added to the cells, followed by
incubation at 37 °C for 60 minutes with shaking at 250 rpm. The cells were then
collected by centrifugation for 10 min at 13200 rpm. The supernatant, except for
100 µL, was removed by aspiration.

The cells were resuspended in the

remaining liquid, and plated on LB containing 2% BactoTM agar and the
appropriate selection antibiotic (50 µg/mL ampicillin or kanamycin).

After

overnight incubation, single colonies were restreaked onto LB plates containing
the appropriate antibiotic selection. Single colonies from the double selection
were then cultured for plasmid biosynthesis (section 2.6.5).
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2.6.5 Plasmid Mini-Prep
A single colony of XL1 blue containing the plasmid of interest was cultured
in 12 mL of LB media containing the appropriate antibiotic selection (50 µg/mL
ampicillin or kanamycin). The culture was grown overnight at 37 °C with 250 rpm
shaking. Cells were collected by successive centrifugation (1 min, 13200 rpm) in
two 1.5 mL epitubes, removing the supernatant by aspiration after each
centrifugation. The cells were resuspended and combined in 300 µL of P1 buffer
(QIAgen, 50mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 µg/mL RNAse A). P2 buffer
(QIAgen, 300 µL; 200 mM sodium hydroxide, 1% SDS) was added and mixed by
inversion prior to incubation for 5 minutes at room temperature.

P3 buffer

(QIAgen, 3.0 M potassium acetate, pH 5.5) was pre-cooled on ice, and then 300
µL was added to the lysed cells, which was mixed by inversion and incubated on
ice for 5 minutes. The cell debris was removed by centrifugation (10 minutes x
13200 rpm), and the supernatant was added to a chilled tube containing 540 µL
of isopropanol. After 5 minutes of incubation on ice, the DNA was collected by
centrifugation (10 minutes x 13200 rpm).

The supernatant was removed by

aspiration, and the DNA pellet was air-dried to evaporate the remaining
isopropanol. The DNA was redissolved in 20 µL of water and stored at -20 °C.

2.6.6 Preparation of Salmon Sperm DNA
Transformation of plasmids into yeast is aided by inclusion of small
intercalating DNA from salmon sperm. Dry salmon sperm DNA (250 mg, Sigma
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catalog number 31149) was added to 25 mL of water (to give 10 mg/mL) and
dissolved by shaking overnight. The following day, the solution was boiled in a
water bath for 15 minutes or until homogeneous solution had been reached,
vortexing if necessary. The solution was cooled to room temperature, and 1 mL
aliquots were stored at – 20 °C.

Prior to use for yeast transformations, the

solution was boiled for 5 min, and then cooled on ice for 5 minutes.

2.6.7 Yeast Transformation of Plasmid DNA
Yeast transformations were performed by a combination of treating cells to
make them chemocompetent, and using the salmon sperm DNA to aid DNA
transformation. A transformation solution (for 5 tranformations) was prepared by
thoroughly mixing (vortexing if necessary) 333 µL of 60% PEG 3350, 50 µL of 1M
dithiothreitol (DTT), 50 µL of 2N lithium acetate, and 67 µL of water (to final
concentration 40% PEG 3350, 100 mM DTT, 0.2 N LiAc). Cells from a fresh
yeast plate (1 cm2, 2 days growth) were transferred to the transformation solution
using a sterilized Pasteur pipet and stirred in thoroughly. This mixture of cells in
transformation solution (100 μL) was combined with salmon sperm DNA (10 µL,
10 mg/mL) and plasmid DNA (1 μL, 0.5 mg/mL) and mixed by flicking the
epitubes. The tubes were incubated on ice for 30 minutes, then at 43 °C in a
heat block for 45 minutes, and then returned to ice for 5 minutes. The mixture
was then plated on complete supplemented medium (CSM) containing 2% Bactoagar with amino acid dropout selection for the plasmid(s) of interest (see Table
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2.1) and incubated at 30 °C. After several days (usually 4 to 7 days), single
colonies were selected and restreaked onto plates with the appropriate dropout
selection media to double select colonies containing the plasmid of interest, and
grown at 30 °C for 2-3 days. The plates were then stored at 4 °C wrapped in
parafilm for future use.

Table 2.1. Description of Yeast Expression Plasmids.
Plasmid
Yeast
Bacterial Yeast Expression
Selection Selection
pSH18-34
URA3
Amp
lacZ gene directed
by 8 lexA operators
for β-gal expression
pSH17-4
HIS3
Amp
LexA-B42
pMW112
URA3
Kan
lacZ gene directed
by 8 lexA operators
for β-gal expression
pSA1 T7-SA B42 TRP1
Amp
T7 tagged SA-B42
pSA1 Rpd3-B42
TRP1
Amp
Rpd3-B42
pSA1
HDAC1- TRP1
Amp
HDAC1-B42
B42
pNLexA-HDAC1
HIS3
Amp
LexA-HDAC1-VP16

Source
Peterson64,99

Origene
Cornish63
Peterson64,99
This work
This work
M.K.H. Pflum

2.6.8 Yeast Three Hybrid Assay
Single colonies of the FY250 yeast strain (from the Peterson
laboratory64,65) or V760 strain (from the Cornish Laboratory67, HIS3 selection)
containing Y3H plasmids were grown overnight in 3 mL of CSM selection media
(containing 2% raffinose) with appropriate amino acid complementation (see
Table 2.1 for plasmid selection and Figures 2.7 and 2.8 for plasmid
combinations).

This overnight culture (50 µL) was added to a 96 well plate

(Costar flat bottom transparent, catalog number 07-200-656) containing 197.5 µL
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of CSM media (containing 1% raffinose, 2% galactose) and final concentration
100 µM SAHA-based CIDs (SAHA-biotin B (36) or SAHA-MTX (41), 2.5 µL of 10
mM; 1% DMSO final concentration), or DMSO (1% final concentration) for
control. The SAHA-based CIDs were used at the highest soluble concentration.
For trials that included zymolyase, 5 µL of 5U/µL was added (for 25U per
reaction) in lieu of 5 µL of media. The cultures were incubated at 30 °C with
shaking at 200 rpm for at least 5 hours. The absorbance of the culture was
measured at OD600. The 250 µL of culture was then transferred to an epitube,
and the cells were collected by centrifugation at 4400 rpm for 5 minutes. The
media was then removed by aspiration, and the cells were resuspended in 200
µL of Z buffer (0.06 M Na2HPO4 0.04 M NaH2PO4, 0.1 M KCl, 0.001 M MgSO4,
0.05 M β-mercaptoethanol, pH 7.0) and treated with 1 drop of chloroform and 2
drops of 0.1% SDS to induce poration to allow the reagents to diffuse through the
yeast membrane81. Samples were then vortexed for at least 30 seconds, and
100 µL of ο-nitrophenyl-β-D-galactoside (ONPG, 4 mg/mL in 0.1 M phosphate
buffer, pH 7.5) was added to each tube. Samples were incubated at 30 °C.
Once samples had developed a yellow color (30-60 minutes), the reaction was
quenched with sodium carbonate (1M, 50 µL).

Cell debris was removed by

centrifugation (13200rpm, 5 minutes) and the absorbance (OD420) of the clarified
supernatant (150 µL) was measured.

Values for the ONPG assay were

expressed as units of β-galactosidase activity = (OD420)/[OD600 x volume of
culture (mL) x time (minutes)]. For a typical assay, the volume of culture used to
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measure OD600 was 0.25 mL and the time for ONPG was the time between
addition of ONPG and quenching with sodium carbonate (typically 30-60
minutes).

2.7 Construction of HDAC-B42 Yeast Expression Plasmids
Yeast expression plasmids encoding for HDAC1-B42, HDAC1(H141A)B42 (catalytically inactive HDAC1 mutation) and Rpd3-B42 (Rpd3 is the yeast
HDAC class I homolog) hybrid proteins were cloned for use as the “bait” in the
Y3H assay. Genes for these hybrid proteins were amplified by polymerase chain
reaction (PCR) (section 2.7.3) and inserted into linearlized plasmid (section 2.7.4)
through homologous recombination in chemocompetant KC8 E. coli102 (section
2.7.1 and section 2.7.4).
First plasmid pSA1 EcoRI-HDAC1-B42-EcoRI-XhoI (Figure 2.9) was
created from pSA1 T7-SA (TRP1, Pgal1, AdhT, 2μ, ampR) with an NcoI restriction
site between the DNA encoding for HDAC1 and DNA for B42.

To facilitate

cloning other HDAC-B42 fusion proteins, pSA1 EcoRI-HDAC1-B42-EcoRI-XhoI
was further modified to remove the second EcoRI restriction site, which also
restored the HA tag on the C-terminus of B42 fusion protein to create plasmid
pSA1 HDAC1-B42 (Figure 2.10). Plasmids pSA1 HDAC1(H141A)-B42 and pSA1
Rpd3-B42 were cloned by inserting HDAC1(H141A) or Rpd3 cDNA respectively,
into pSA1 HDAC1-B42 after EcoRI/NcoI restriction digest to remove HDAC1
(section 2.7.2).
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EcoRI

GAL1
pUC ori
HDAC1

AMP
pSA1 EcoRI-HDAC1-B42 EcoRI-XhoI

NcoI

B42

EcoRI

7350bp
XhoI
ADHT

TRP
2 um origin

Figure 2.9. Plasmid Map of pSA1 EcoRI-HDAC1-B42-EcoRI-XhoI.
First yeast expression plasmid cloned for the expression of HDAC1-B42
under control of a GAL1 promoter and Adh termination domain. Relevant
restriction sites are displayed including EcoRI site before HDAC1 and
immediately after
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EcoRI

GAL1
pUC ori
HDAC1

AMP

NcoI

B42

pSA1 HDAC1-B42
7350bp

XhoI
ADHT

TRP
2 um origin

Figure 2.10. Plasmid Map of pSA1 HDAC1-B42. Yeast expression
plasmid of HDAC1-B42 lacking the second EcoRI restriction site.
Expreesion of HDAC1-B42 in under control of a GAL1 promoter and Adh
termination domain. Other important features include ampicillin resistance
in bacteria, and TRP1 selection in yeast.

95
2.7.1 Preparation of Chemocompetant KC8 E. coli
Cloning was performed using homologous recombination in chemically
competent KC8 E. coli. Similar to yeast, bacteria have been used for their native
in vivo homologous recombination function102-104. The KC8 strain was a gift from
the Finley lab at Wayne State University, who has previously shown this strain is
efficient for high-throughput recombinant cloning102.

Cells were prepared for

chemocompetency prior to DNA transformation. A 5 mL liquid culture of KC8
was grown overnight in LB media at 37 °C with 250 rpm shaking. The culture
was then added to 500 mL of LB media, and incubated at 37 °C with 250 rpm
shaking until the OD600 was 0.5, or about 3 hours. The cells were collected by
centrifugation at 3500 rpm for 15 min at 4 °C, and the media was removed. The
cells were resuspended in 25 mL of pre-chilled TSB (LB adjusted to pH 6.1 with
dilute aqueous HCl, 10% (w/v) PEG 3400, 5% (v/v) DMSO, 10% (v/v) glycerol, 10
mM MgCl2, 10 mM MgSO4), and incubated for 10 minutes on ice. Aliquots (250
µL, approximately 5 transformations) were flash frozen in an ethanol-dry ice
solution and stored at -80 °C.

2.7.2 Restriction Enzyme Digest
Plasmids were linearlized using bacterial restriction enzymes prior to
homologous recombination105. Restriction enzymes (Promega: EcoRI, XhoI and
NcoI; catalog numbers: R6011 R6161; R6513 respectively) and plasmids (for
details see Table 2.2) were combined in 1X Buffer H (Promega) to a total volume
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of 20 μL (0.1 mg/mL BSA), and incubated at 37 °C with shaking at 250 rpm. To
prevent the plasmids from religating after digestion, calf intestinal phosphatase (1
µL of 10000U/mL, NEB cat # M0290S) and 10X NEB buffer 3 (2 µL, 1 M NaCl,
500 mM Tris-HCl, 100 mM MgCl2, 10 mM dithiothreitol, pH 7.9) were added to
the reaction after 2 hours, and was incubated as above for an additional 60
minutes.

The linearlized plasmid was purified by gel electrophoresis [1%

agarose in Tris-Acetate-EDTA buffer (TAE; 40 mM Tris, 20 mM acetate, 1 mM
EDTA, pH 8.5, 0.5 μg/mL ethidium bromide)] for 60 minutes at 200V, extracted
using QIAgen gel extraction spin kit (cat # 28704) and eluted into 30 µL of water
for use in homologous recombination (section 2.7.4).

Table 2.2. Description of Restriction Enzyme Digest Reactions.
Target plasmid
pSA1 EcoRI-HDAC1B42-EcoRI-XhoI
pSA1 HDAC1-B42
pSA1
HDAC1(H141A)-B42
pSA1 Rpd3-B42

Parent plasmid
pSA1 T7-SA (1μL, 0.5
μg/μL)
pSA1
EcoRI-HDAC1-B42EcoRI-XhoI (1 μL, 0.5 μg/μL)
pSA1 HDAC1-B42 (1μL, 0.5
μg/μL)
pSA1 HDAC1-B42(1 μL, 0.5
μg/μL)

Restriction Enzymes
EcoRI; 1μL of 10U/μL
XhoI; 1μL of 10U/μL
NcoI; 1μL of 10U/μL
XhoI; 1μL of 10U/μL
EcoRI; 1μL of 10U/μL
NcoI; 1μL of 10U/μL
EcoRI1μL of 10U/μL
NcoI; 1μL of 10U/μL

2.7.3 Polymerase Chain Reaction (PCR)
DNA encoding for HDAC-B42 hybrid proteins were amplified using a PCR
touch down program. The PCR insert for EcoRI-HDAC1-B42-EcoRI-XhoI was
created in a two-step PCR sequence. In the first step, HDAC1 sequence was

97
amplified from p424 HDAC1-LexA plasmid106 using forward primer pSA1-EcoRIHDAC1(for)

5ʼ-

AACGTCAAGGAGGAATTAACTATAGAATTCATGGCGCAGACGCAGGGCACC
and

reverse

primer

HDAC1-NcoI-B42(rev)

5ʼ-

CTTTTTTGGAGGAGCACCCATCCATGGGGCCAACTTGACCTCCTCCTT. B42
cDNA was amplified from the Peterson plasmid pSA1 T7-SA65 to include the
nuclear localization signaling domain using forward primer HDAC1-NcoI-B42(for)
5ʼ-AAGGAGGAGGTCAAGTTGGCCCCATGGATGGGTGCTCCTCCAAAAAG
and

reverse

primer

pSA1(rev)

5ʼ-

GAAGTGTCAACAACGTATCTACCAACGATTTGACCC. Samples were prepared
on ice in 0.5 mL epitubes by combining in order: water (30 µL), DMSO (5 µL),
10X Pfu buffer (5 µL of 200 mM Tris, 100 mM (NH4)2SO4, 100 mM KCl, 1% Triton
X-100, 20 mM MgSO4, 1 mg/ml BSA, pH 8.8), DNA plasmid template (1 μL of 0.5
µg/μL), forward (1 μL of 12.5 pmol/μL) and reverse primers (1 μL of 12.5
pmol/μL), and dNTPs (5 μL of 10 mM; 2.5mM of each base). Samples were
mixed thoroughly and centrifuged briefly, then heated in thermocycler (Eppendorf
Mastercycler Gradient) for 1 minute at 95 °C prior to addition of Pfu enzyme (2
µL, for a final volume of 50 μL). After addition of the enzyme, the touch down
program began with 10 cycles with decreasing annealing temperatures as
follows: 1 minute at 95 °C to disrupt all binding interactions, followed by 1 minute
at annealing temperature, and 2 minutes at 72 °C for DNA elongation. The initial
annealing temperature was 65 °C and final annealing temperature of 55 °C.
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Following the initial 10 cycles, 25 cycles matching the tenth cycle at the final
annealing 55 °C were performed.

The PCR cycles ended with a 10 minute

elongation period at 72 °C before cooling to 4 °C.
A second PCR step was used to create the full length EcoRI-HDAC1-B42EcoRI-XhoI insert for homologous recombination. Extracted PCR products of
HDAC1 cDNA (0.5 μL from above) and B42 (0.5 μL from above) were combined
in a 0.5 mL epitube on ice. Water (30 µL) was added followed by DMSO (5 µL),
10X Pfu buffer (5 µL), forward primer pSA1-EcoRI-HDAC1(for) (1 μL of 12.5
pmol/μL), reverse primer pSA1(rev) (1 μL of 12.5 pmol/μL), and dNTPs (5 μL of
10 mM; 2.5mM of each base). Samples were mixed thoroughly and centrifuged
briefly, then heated in thermocycler (Eppendorf Mastercycler Gradient) for 1
minute at 95 °C prior to addition of Pfu enzyme (2 µL, for a final volume of 50 μL).
The same touchdown program was used in the second PCR step with an initial
annealing temperature of 65 °C and final annealing temperature of 55°C.

The

PCR product (10 μL) was verified by gel electrophoresis (as above), but the
majority of (40 μL) was purified using QIAquick PCR purification kit (catalog
number 28104), and eluted into 30 µL of water. The purified PCR sample was
transformed immediately with fresh restriction digest product (section 2.7.2) into
KC8 E. coli for homologous recombination (section 2.7.4).
The HDAC-B42 PCR insert for cloning HDAC1-B42 lacking the second
EcoRI restriction site, was amplified from plasmid pSA1 EcoRI-HDAC1-B42EcoRI-XhoI using forward primer pSA1-EcoRI-HDAC1(for) and new reverse
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primer

B42-XhoI-pSA1(rev)

CAAAGCTTCTCGACTCACTCGAGGGGAGAGGCATAATCTG.

5ʼThe

PCR

samples were prepared following the same protocol as above. Three samples
were prepared on ice in 0.5 mL epitubes by combining in order: water (30 µL),
DMSO (5 µL), 10 x Pfu buffer (5 µL) DNA plasmid template (1 μL of 0.5 µg/μL),
forward (1 μL of 12.5 pmol/μL) and reverse primers (1 μL of 12.5 pmol/μL), and
dNTPs (5 μL of 10 mM; 2.5mM of each base). Samples were mixed thoroughly
and centrifuged briefly, then heated in thermocycler (Eppendorf Mastercycler
Gradient) for 1 minute at 95 °C prior to addition of Pfu enzyme (2 µL, for a final
volume of 50 μL). After addition of the enzyme, the touch down program began
as above with an initial annealing temperature of 65 °C and final annealing
temperature of 55 °C. The three PCR samples were combined and purified by
gel electrophoresis (as above) for 60 minutes at 200V, then extracted into 30 µL
of water using QIAquick gel extraction spin kit (catalog number 28704). The
purified PCR sample was transformed immediately with fresh restriction digest
product (section 2.7.1) into KC8 E. coli for homologous recombination (section
2.7.4).
For cloning Rpd3-B42 encoding plasmid into pSA1 HDAC1-B42, the Rpd3
insert was amplified from plasmid YEplac112-Rpd3-LexA-FLAG106 with the
forward

primer

pSA1-EcoRI-Rpd3(for)

CGTCAAGGAGGAATTAACTATAGAATTCATGAGTTATGAAGC
primer

Rpd3-NcoI-B42(rev)

5ʼand

reverse
5ʼ-
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GGAGCACCCATCCATGGATAGAATTCATTGTCATGCTCAACATGTA following
the method above, but using an initial annealing temperature of 70 °C and final
annealing temperature 60 °C. In a similar manner, HDAC1(H141A) insert was
amplified from p424 HDAC1(H141A)-LexA (modified by Sujith Weerasinghe from
p424 LexA-HDAC1106) using forward primer pSA1-EcoRI-HDAC1(for) and
reverse primer HDAC1-NcoI-B42(rev) with initial annealing temperature 65 °C
and final annealing temperature 55 °C.

2.7.4 Homologous Recombination in KC8 cells
For this application PCR inserts were combined with linearlized plasmid in
different ratios in chemocompetent KC8 E. coli cells (section 2.7.1). The most
successful results were obtained when chemocompetant KC8 cells (50 µL,
section 2.7.4) pre-thawed on ice were combined with 5 µL of PCR insert (section
2.7.3) and 5 µL of linearlized plasmid (section 2.7.2) in a 1X KCM buffered
solution (final concentration 0.1 M potassium chloride, 30 mM calcium chloride,
50 mM magnesium chloride). The cells were incubated on ice for 20 minutes,
followed by heat shock at 42 °C for 30 to 45 seconds and cooled on ice for an
additional 5 minutes. 500 µL of LB media was added and cells were incubated at
37 °C with shaking at 250 rpm for 60 to 90 minutes. Cells were collected by
centrifugation at 13200 rpm for one minute; the solution was removed except for
about 150 µL. The cells were resuspended in the remaining liquid and plated
onto LB agar plates (containing 20 µg/mL kanamycin for KC8 selection and 50
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µg/mL ampicillin for selection of new plasmids). After overnight incubation at 37
°C, colonies were restreaked for double selection on LB plates (as above).
Several double selected colonies were then mini-prepped (section 2.6.3) and
analyzed by restriction digest and PCR before submitting for sequencing.
Successfully cloned plasmids were transformed into XL1 blues for larger scale
plasmid synthesis.
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CHAPTER 3
IN VITRO HDAC INHIBITOR ASSAY DEVELOPMENT

3.1 In vitro Competitive Inhibitor Screening
3.1.1 Introduction to Competitive Inhibitor Screening In Vitro
Due to their role in regulating gene expression, Class I HDAC enzymes
have been identified as targets for cancer therapeutics. Advancement in the
discovery of selective HDAC inhibitors against Class I enzymes has been limited
by a lack of technology for screening inhibitors against individual HDAC isoforms;
a high-throughput screening method could significantly improve current methods
of identifying selective HDAC inhibitors.

A competitive inhibitor screen was

developed using a yeast three hybrid system, but the impermeability of SAHAbased CIDs towards the yeast cells presented significant obstacles towards
screening HDAC inhibitors in yeast (Chapter 2).
As an alternative to screening HDAC inhibitors using the Y3H system, this
Chapter outlines a competitive HDAC inhibitor screen in vitro. HDAC inhibitors
will be screened from HeLa lysates and probed using antibodies, which
specifically bind to individual HDAC isoforms (see section 3.2.3 for details). A
major advantage to this method over the Y3H is that competitive inhibitors will be
screened only for binding interaction without the complication of yeast cell
permeability. In addition, there is no need to grow yeast overnight, resulting in a
shortened assay that can be performed in a few hours.
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The in vitro competitive HDAC inhibitor assay was inspired by previous
work done by Ambit biosciences in their development of an in vitro selective
kinase inhibitor assay (section 1.4.1).83,107

The kinase in vitro assay was

developed around a CID composed of biotin linked to a non-selective kinase
inhibitor, similar to the SAHA-biotin CIDs developed in Chapter 2 for the Y3H
assay (section 2.2.4). In the assay, individual kinase proteins were expressed on
T-7 bacteriophage produced in E. coli followed by PCR amplification for detection
of unbound (or competitively inhibited) proteins. This method was not applicable
to HDAC proteins due to improper folding of HDAC proteins when expressed in
bacterial systems, which we verified prevents SAHA-biotin CID binding to HDAC1
(section 3.2.2). Alternatively, HDAC proteins could be isolated from HeLa lysates
by immunoprecipitation (section 3.2.3).

3.1.2 In vitro HDAC Inhibitor ELISA Assay
Towards the goal of high throughput inhibitor screening, we developed an
HDAC-based ELISA for screening HDAC inhibitors against individual HDAC
isoforms. For this application, the use of a SAHA-biotin CID allowed for isolation
and detection of HDAC proteins from cellular lysates by taking advantage of the
strong interaction between biotin and streptavidin (SA) or streptavidin analogs108.
Using this method, secondary anti-rabbit antibody coated plates were coated with
primary anti-HDAC1 antibody from rabbit (Figure 3.1).

The wells were then

treated with HeLa lysates in the presence of SAHA-biotin CID B (36), followed by
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streptavidin-horse radish peroxidase (SA-HRP) complex and HRP substrate,
allowing for easy detection of the HDAC1 interaction with SAHA-biotin CID B (36)
(Figure 3.1 A). Competitive HDAC inhibitors could then be used to disrupt the
HDAC binding to the complex, resulting in the SA-HRP complex being washed
away, and a lack of signal (Figure 3.1 B).
The HDAC-based ELISA was developed as a competitive screening tool
for screening selective HDAC inhibitors against individual HDAC isoforms.
Unlike the current fluorescence method for screening HDAC inhibitors, this assay
would not monitor the inhibition of deactylase activity by inhibitors, but would
represent binding affinity to HDAC proteins.

Significantly, this method would

include isolation of individual HDAC isoforms, unlike the current assay, which
includes all the HDAC proteins present in HeLa lysates and does not assess
selectivity. In addition, this assay would offer a widely accessible method for
screening competitive HDAC inhibitors compared to the mass spectrometric
analysis used to screen HDAC inhibitors in the in vitro screen discussed in
section 1.4.2.

To assess the viability of the ELISA-based HDAC assay, SAHA-

Biotin CIDs (for synthesis see section 2.2.4) was used for isolation of HDAC
proteins from cellular lysates using NeutrAvidin beads followed by western blot
analysis (section 3.2.1), and ultimately for detection in an HDAC-dependent
ELISA (section 3.2.4).
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A

B
= SAHA-Biotin
Sub.
HRP

CID
WASH AWAY
LOSS OF SIGNAL

SA

= Competitive
HDAC inhibitor

CID
HDACX

HDACX

Figure 3.1. HDAC Inhibitor ELISA. Individual wells from 96-well plate
represented; primary antibody represented by Y at bottom of the wells;
HDACX represents the different HDAC proteins that could be isolated in
this assay; HDAC proteins isolated from HeLa lysates. A) In the presence
of SAHA-Biotin CID, SA-HRP complex is recruited, and HRP substrate is
cleaved resulting in a detectable signal. B) In the presence of a
competitive HDAC inhibitor, SA-HRP complex will be washed away,
leading to a lack of signal from the HRP substrate (Sub).
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3.2

Results

3.2.1 CID Binding Using NeutrAvidin Beads
As a proof of concept that the SAHA-biotin CID could be used to isolate
HDAC proteins in vitro, NeutrAvidin beads were employed to precipitate HDAC
proteins from cellular lysates.

HeLa lysates were used in these initial

experiments because they are a common source of human HDAC proteins.
Lysates were incubated with SAHA-biotin CID A (22) followed by NeutrAvidin
beads (Figure 3.2 A) and analyzed by western blot analysis (Figure 3.2 B).
Isolation of HDAC1 was shown to be dependent on the concentration of CID
used, and was self-competed if a high concentration of CID was used; best
results were obtained using lysates incubated with 1 μM SAHA-biotin CID, with
less signal observed for lysates incubated with 10 μM CID, and no signal
observed for lysates incubated with 100 μM SAHA-biotin CID (Figure 3.2 B).
This method was then modified to pre-coat the NeutrAvidin beads with
SAHA-biotin CID B (36) prior to treatment with HeLa lysate in order to eliminate
self-competition, which is the same protocol used in the kinase selectivity assay
(section 1.4.1). 83,84 First, we demonstrated that HDAC1 and HDAC2 bound nonspecifically to the NeutrAvidin beads in the absence of SAHA-biotin CID (Figure
3.3 A, (-) SAHA-biotin CID lane), but this non-specific interaction could be
avoided if lysates were first pre-cleared in the presence of NeutrAvidin beads
prior to treatment with beads coated in SAHA-biotin CID B (Figure 3.3 B, (-)
SAHA-biotin CID lane). Using the pre-clearing method high abundant HDAC1-3,
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0
Lysate

1

10

100

CID (μM)

Figure 3.2. Isolation of HDAC from lysates using SAHA-Biotin CID
and NeutrAvidin beads. A) Binding complex of SAHA-Biotin with HDAC
and NeutrAvidin beads. B) Western blot analysis (anti-HDAC1) of HDAC1
isolated by NeutrAvidin beads with varying concentrations of SAHA-Biotin
CID A.
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anti-HDAC1
anti-HDAC2
Lysate

(-)

(+)

anti-HDAC3

SAHA-Biotin
CID B

anti-HDAC5
anti-HDAC6
anti-HDAC7
anti-HDAC10
Lysate

(-)
(+)
SAHA-Biotin
CID B

Figure 3.3. Isolation of HDAC Proteins From HeLa Lysates using
SAHA-Biotin CID B Coated NeutrAvidin Beads. Western blot analysis
(antibodies indicated to the right of figure) of HDAC protein isolation with
NeutrAvidin beads either in the absence of SAHA-biotin CID (-), or precoated with 1 µM SAHA-Biotin CID B (36) (+). A) HDAC1 and HDAC2
isolation in the absence of pre-clearing HeLa lysates with NeutrAvidin
beads; lysate lane is 20% loading of HeLa lysates. B) Isolation of HDACs
1-3, 5-7, and 10 from HeLa lysates pre-cleared with NeutrAvidin beads
prior to pulldown experiment; lysate lane is 10% loading of HeLa lysates
except for HDAC2 (20% loading).

109
6 and 10 were isolated using the SAHA-biotin CID (36), while HDACs 5 and 7
were not isolated (Figure 3.3 B). HDAC6 was isolated with high signal compared
to the lysate control lane (10% loading) in relation to the other HDAC proteins,
indicating that the SAHA-biotin CID B (36) may have higher affinity towards
HDAC6 (further assessment with the HDAC activity assay required).

These

results show a proof of concept that the SAHA-biotin CID is affective for isolation
of individual HDACs 1-3, 6 and 10. To allow access to the individual HDAC
isoforms, antibody isolation using secondary antibodies in a high throughput
plate-based ELISA was developed (Section 3.2.4).

3.2.2 CID binding to HDAC1 expressed in BL21 E coli
With the knowledge that SAHA-biotin CID was able to precipitate HDAC
proteins from human cellular lysates, we next tried to precipitate human HDAC1
expressed in BL21 strain of E coli, which could provide a facile expression of
individual HDAC isoforms. HDAC1 has previously been reported to lack activity
when expressed in bacterial systems6, but whether this loss of activity affects
inhibitor binding was still in question.

To answer this question, HDAC1 was

expressed in the bacterial system, and lysates were incubated with various
concentrations of SAHA-biotin CID followed by NeutrAvidin beads (Figure 3.4).
This experiment confirmed that although HDAC1 is present in the lysates (Figure
3.4, lysate lane), the SAHA-biotin CID was not effective in isolating these proteins
(Figure 3.4, 1 µM, 10 µM and 100 µM SAHA-biotin CID lanes). These results are
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consistent with the improper folding of HDAC1 in bacterial expression systems
that not only affects activity, but also inhibitor binding to the active site of HDAC1.
An alternate method of isolating individual HDAC proteins was needed.

anti-HDAC1
Lysate

0

1

10

100

CID (μM)
Figure 3.4. SAHA-Biotin CID Treated BL21 Lysates Expressing
Human HDAC1. Western blot analysis (anti-HDAC1) of HDAC1 from
NeutrAvidin beads with varying concentrations of SAHA-Biotin CID. Lane
1: lysate (5% loading), lane2: 0 µM CID; lane 3: 1 µM CID; lane 4: 10 µM
CID; lane 5: 100 µM CID.

3.2.3 Immunoprecipitation (IP) of Individual HDAC Proteins
In order to obtain well-folded human HDACs from lysates, HeLa cells
containing the majority of HDACs were used, and individual HDAC proteins were
isolated by IP.

A limiting factor to this method is the known interactions of

several of the HDAC isoforms with each other, which could give misleading
results when screening inhibitors for isoform selectivity. Specifically, HDAC1 and
HDAC2 have been shown previously to co-IP from HeLa lysates.109 In addition,
HDAC3 been shown to co-IP with Class IIb HDACs 4 and 7.110,111

The

interaction between HDAC1 and HDAC2 was observed through co-IP, confirming
the previously reported results (Figure 3.5 A).109
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In order to screen individual HDAC isoforms, isolation of individual HDAC
from complexes was required for accurate selectivity screening. In an effort to
isolate these proteins individually, lysates were pre-cleared with protein A
agarose resin (used in the IPs to precipitate the antibodies) prior to IP. Using this
pre-clearing method, HDAC1 and HDAC2 could be isolated individually (Figure
3.5 B), demonstrating that this method could be used to screen HDAC inhibitors
against these individual HDAC isoforms.

A

B
anti-HDAC1
anti-HDAC2
Lysate

1

2

Lysate

Control

1

2

Figure 3.5. Co-IPs of HDAC1 and HDAC2. Western blot analysis
(antibodies indicated to the right of figure) of HDAC1 and HDAC2 Co-IPs
from HeLa lysates; lysate lane is 10% loading of HeLa lysates; control is in
the absence of antibody; 1 indicates HDAC1 IP; 2 indicates HDAC2 IP. A)
IPs performed in the absence of lysate pre-clearing with protein A
agarose. B) Lysates pre-cleared with protein A agarose prior to IPs.

With a feasible method for isolating HDAC1 and HDAC2 individually, we
next wanted to isolate each of the human HDAC proteins. Using the pre-clearing
method, HDAC proteins were isolated from HeLa lysates using protein A agarose
resins conjugated to individual HDAC 1-8 and 10-11 antibodies; HDAC9 was not
detected in the HeLa lysates (data not shown). Under these conditions, HDAC1
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through HDAC7 and HDAC10 have been isolated individually through IP with the
antibody-conjugated protein A resins (Figure 3.6). IPs of HDAC8 and HDAC11
were unsuccessful with the available antibodies, but were detected by western
blot analysis (see Appendix B.2.2). Importantly, each isoform could be isolated
individually, demonstrating that HeLa lysates are an appropriate source of
individual HDAC isoforms for screening HDAC inhibitors.

With conditions

established where the individual HDAC isoforms could be precipitated separately
we worked towards development of an HDAC-dependent ELISA (section 3.2.4).

anti-HDAC1
anti-HDAC2
anti-HDAC3
anti-HDAC4
anti-HDAC5
anti-HDAC6
anti-HDAC7
anti-HDAC10
Lys C

1

2

3

4

5

6

7

8

10 11

Figure 3.6 HDAC Co-IPs from HeLa Lysates. Individual HDACs (lanes
across bottom of gel) were immunoprecipitated from HeLa lysates,
separated by SDS-PAGE, followed by western blot analysis with
antibodies indicated to the right (Lys = 10% of input, C = Control, no
antibody).
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3.2.4 HDAC-Dependent ELISA
To establish our HDAC inhibitor assay in a high-throughput format, an
inhibitor based ELISA is under development. To our knowledge this is the first
ELISA assay that relies of small molecule-protein interaction.

For this

application, 96-well plates coated in secondary anti-rabbit antibody were treated
with anti-HDAC1 to isolate the individual HDAC1 isoform.

Plates were then

treated with HeLa lysates containing SAHA-Biotin CID, followed by SA-HRP
compex, and visualized with an HRP substrate (Figure 3.1).
First, we established that the assay was dependent on the concentration
of SAHA-biotin CID B (36) by including varying concentrations of SAHA-biotin
(Figure 3.7). The background signal OD450 was observed at around 0.13 with no
increase in signal observed at 0.01 µM or 0.1 µM (Figure 3.7). Minor increase in
signal was observed at 1 µM (OD450 = 0.167), 2.5 µM (OD450 = 0.255) and 5 µM
(OD450 = 0.305), with significant increase in signal at 10 µM (OD450 = 0.517) and
20 µM (OD450 = 1.03) concentration of SAHA-biotin CID B (36) (Figure 3.7). For
future experiments 10 µM SAHA-biotin CID B (36) concentration was used.
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Figure 3.7. HDAC1-Dependent ELISA With Varying Concentration of
SAHA-Biotin CID B (36). HeLa lysates were treated with varying
concentration of SAHA-biotin CID B (36) (µM concentrations listed below
bars) and absorbance of HRP substrate, TMB, was measured at 450 nm.
Results are the average of two simultaneous trials.

Once we established the dose-dependence of SAHA-biotin CID B (36), we
next demonstrated the ability to disrupt the system by pre-incubating lysates with
varying concentrations of competitive SAHA (Figure 3.8). Similar to the results
from Figure 3.6, high signal was observed in the ELISA with 10 µM SAHA-biotin
B compared to the control lane in the absence of CID (Figure 3.8, lanes 1 and 2).
SAHA was pre-incubated with the HeLa lysates for 10 minutes prior to the
addition at SAHA-biotin CID B in the last 5 columns (Figure 3.8); a slight
decrease was observed with an equal concentration of SAHA (10 µM) compared
to SAHA-biotin CID B alone (Figure 3.8, lanes 3 and 2). With the addition of 10fold and 20-fold excess of SAHA (100 µM and 200 µM) the signal was decreased
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by about half (Figure 3.8, lanes 4 and 5). Significant decrease in signal from the
HDAC-dependent ELISA was observed with 50-fold and 100-fold excess of
SAHA (500 µM and 1000 µM). These results provide evidence that the HDACdependent ELISA may be a useful screening tool for competitive HDAC inhibitors
through disruption of the HDAC-binding to the SAHA-biotin CID.
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Figure 3.8. HDAC1-Dependent ELISA With Varying Concentration of
Competitive SAHA. HeLa lysates were treated with 10 µM SAHA-biotin
CID B (36) in the presence of varying concentration of SAHA (µM
concentrations listed in table below below bars) and absorbance of HRP
substrate, TMB, was measured at 450 nm. Results are from a single trial.
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3.2.5 Conclusions and Future Directions
The results from the HDAC-dependent ELISA are still preliminary. Once
we have established reproducibility and optimized conditions, other HDAC
isoforms will be used to establish that this assay is applicable for isoform
selectivity screening. The assay will then be used to screen competitive small
molecules other than SAHA to confirm the system is useful for screening a
variety of HDAC inhibitors.

3.3

Biochemical methods

3.3.1 General Materials
Reagents were generally purchased from Fisher Scientific, Acros Organics
or Sigma Aldrich unless otherwise noted; Yeast Nitrogen Base without amino
acids, BactoTM Agar, BactoTM peptone and Yeast Extract were purchased from
Difco; dried milk was purchased from the grocery store.

3.3.2 General Equipment
The Pflum lab is equipped with standard biochemical equipment including
centrifuges (Eppendorf models 5415D and 5810R), bacterial incubator/shaker
(New Brunswick Scientific C25 Incubator Shaker Classic Series), a Tecan
GENios Plus spectrophotometer, a VWR rocking platform, and a Barnstead
Thermolyne Labquake shaker rotisserie.
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3.3.3 HeLa Cells Lysis
HeLa cells were purchased from Biovest Inc. in aliquots of 1 x 109 cells
frozen to – 80 °C. Tubes were lysed by adding 9.0 mL of Jurkat Lysis Buffer
(JLB; 50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 10 % glyercol, 0.5%
Triton X-100) and 100 µL of 100X Calbiochem protease inhibitor cocktail V
(catalog number 539137) and rotating at 4 °C for 30 minutes. The tube was
thoroughly mixed by pipetting up and down to ensure complete cell lysis.

The

cell debris was then removed by centrifugation at 12000 RPM at 4 °C for 30
minutes. The lysate was then assessed for protein content (mg/mL) using BioRad protein assay (Bradford reagent, catalog number 500-006). Hela cell lysates
from 106 cells in 100 µL of JLB typically contained 5-15 mg/mL. Aliquots were
stored at -80 °C and thawed at 4 °C prior to use.

3.3.4 NeutrAvidin Bead Pulldown with SAHA-Biotin CIDs
Method A. The initial concentration-dependent NeutrAvidin bead pulldown
experiments were performed using SAHA-biotin CID A (22).

For this

experiment, 100 µL of HeLa lysates (section 3.3.1 from approximately 106 cells;
typically 5-15 mg/mL) containing SAHA-biotin CID A (22) (1 µM, 10 µM, or 100
µM; 1% DMSO final concentration) were added to NeutrAvidin agarose resin (20
µL of suspended resin, 80 nmol biotin/mL resin, Pierce catalog number 29200).
The tubes were incubated overnight at 4 °C with rotation. The following morning
the resin was centrifuged at 1000 x g for 1 minute, and the liquid was removed by
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aspiration. The resin was washed 3 times with cold JLB (1 mL) following the
same protocol. SDS loading buffer (10 µL, 50 mM Tris-Cl, 100 mM DTT, 2%
(w/v) SDS, 0.1% bromophenol blue, 10% glycerol) was added to the resin, which
was then incubated at 95 °C for more than 60 seconds to disrupt the binding
interactions.

Samples were then separated by SDS-PAGE electrophoresis

(section 3.3.7) and analyzed by western blot (section 3.3.9) with primary antiHDAC1 from rabbit (1:10,000 in PBST containing 10% dried milk (w/v), 60
minutes at room temperature; Sigma catalog number H3284) and secondary antirabbit peroxidase (1:10,000 in PBST containing 10% dried milk (w/v), 60 minutes;
Sigma catalog number A9169).

The western blot for this experiment was

visualized using SuperSignal® west fempto maximum sensitivity substrate kit
(catalog number 34094) following the manufacturerʼs instructions. Western blots
were visualized using a Typhoon 9210 variable mode imager (Amersham
Biosciences) measuring luminescence.

Method B. The NeutrAvidin bead pulldown experiments were performed using
SAHA-biotin CID B (36). For these experiments, NeutrAvidin agarose resin (20
µL of suspended resin, 80 nmol biotin/ml resin, Pierce catalog number 29200)
was added to spin columns (Pierce catalog number 69705) and the liquid was
removed by centrifugation at 1000 x g for 1 minute. The resin was then washed
three times with Pierce IP Lysis/wash buffer (200 µL; 25 mM Tris, 15 mM sodium
chloride, 1 mM EDTA, 1% NP-40 or Igepal, 5% glycerol; pH 7.4), centrifuging
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after each wash to remove the liquid. The spin columns were then closed with a
plug, and 100 µL of 1µM CID solution (1% DMSO in IP Lysis/wash buffer) was
added to the columns; columns were sealed with screw cap, and incubated
overnight with rotation at 4 °C. The following morning the resin was centrifuged
at 1000 x g for 1 minute to remove the CID solution. Precleared HeLa lysates
(100 µL, 5 mg/mL; section 3.4.1) were diluted with Pierce IP Lysis/wash buffer (to
300 µL), and this solution was added to the CID coated resin. The spin columns
were sealed and incubated for 2 hours at 4 °C with rotation. The lysates were
removed by centrifugation and the resin was washed three times with Pierce IP
Lysis/wash buffer (200 µL). The bound proteins were then eluted from the beads
by adding 10 µL of elution buffer (Pierce Kit 26147, primary amine, pH 2.8) to the
spin columns and centrifuged (1 minute at 1000 x g). The eluent was collected
into clean 1.5 mL epitubes containing 2.5 µL of 1 M Tris (pH 9.5 to neutralize the
acidic elution buffer). An additional 30 µL of elution buffer was added to each
spin column and incubated at room temperature for 5 minutes, then collected (1
minute a 1000 x g) into the same epitube as the first elution. 5X SDS loading
buffer (11 µL) was added to the eluted protein solution and the tubes were
heated to 95 °C for at least 1 minute. The samples were then loaded onto SDSPAGE gels (section 3.3.7) and analyzed by western blot (section 3.3.9).
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3.3.5 HDAC1 expression in BL21 E. coli
HDAC1 bacterial expression plasmid pET21bHDAC1112 was obtained from
Paulina Karwowska-Desaulniers, who cloned human HDAC1 into commercially
available plasmid pET21b (Novagen catalog number 69741-3).112,113

The

HDAC1 plasmid was transformed into chemocompetant BL21 strain of E. coli
(prepared following the same method described in section 2.6.3) using the
protocol described in Chapter 2 (section 2.6.4). A single colony, selected by
ampicillin resistance, was seeded in a 5 mL culture of LB media containing 50
µg/mL ampicillin and incubated overnight at 37 °C, 250 rpm. The following day,
0.5 mL of this culture was added to 100 mL of LB media containing 50 µg/mL
ampicillin, and grown at 37 °C with 250 rpm shaking until the OD600 was around
0.6 (approximately 3 hours). IPTG (125 µL of 0.8 M; final concentration 1 mM)
was added to the culture to induce protein expression, and cells were incubated
37 °C, 250 rpm for 3 additional hours. Cells were collected at 4000 rpm for 5
minutes and the media was removed. Cells were resuspended and washed with
cold phosphate buffered saline (PBS; 0.01M sodium phosphate, 0.15 M sodium
chloride; pH 7. 2) (3 x 10 mL) and collected by centrifugation after each wash.
The cell pellet was finally resuspended in 4 mL of PBS containing 1 mg/mL of
lysosyme, and incubated on ice for 30 minutes. To the cells was added 10 mL of
0.2% Triton-X 100 and DNAse and RNAse and the tube was shaken vigorously
followed by a 10 minute incubation on ice. The cell debris was then removed at
12000 rpm for 30 minutes and the lysate was treated with DTT to a final
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concentration of 1 mM. The lysates were then adjusted to resemble JLB buffer
by adding glycerol (to 10%), Triton-X 100 (to 0.5%), and 10X PBS (to make 1X
PBS) and final DTT concentration of 0.8 mM. The lysates were aliquoted and
stored at -20 °C. These lysates were then used in the NeutrAvidin CID pulldown
experiment by combining 50 µL of lysates (from approximately 0.286 mL of cell
culture) thawed on ice, with 10 µL of suspended NeutrAvidin beads coated in
SAHA-biotin CID (as described above).

3.3.6 Traditional Immunoprecipitations (IPs) of HDAC1 and HDAC2
The initial IPs (IPs) of HDAC2 were prepared by combining 100 µL of
HeLa lysates (section 3.3.1 from approximately 106 cells) with 2.5 µg of antiHDAC2 antibody from rabbit (Sigma catalog number H3145). The solutions were
incubated overnight at 4 °C with rotation to allow antibody binding to HDAC2.
Protein A agarose resin (20 µL of suspended resin, 12-15 mg human IgG/ml
resin, Pierce catalog number 20333) was added to the antibody-containing lysate
solution, and the reactions were incubated for 2 hours at 4 °C with rotation. The
resin was centrifuged at 1000 x g for 1 minute, and the liquid was removed by
aspiration. The resin was washed 3 times with JLB (1 mL) following the same
protocol. SDS loading buffer (10 µL) was added to the resin, which were then
incubated at 95 °C for more than 60 seconds to disrupt the binding interactions.
Samples were then separated by SDS-PAGE electrophoresis (section 3.3.7) and
western blot analysis (section 3.3.9).
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3.3.7 Preparation of αHDAC conjugated Protein A beads
IPs of HDAC proteins were performed with the Pierce Crosslink IP kit
(Pierce catalog number 26147) where the primary antibodies were covalently
attached to protein A coated agarose beads in the presence of disuccinimidyl
suberate (DSS).

Following the manufacturerʼs protocol, 20 µL of suspended

Pierce Protein A/G Plus resin slurry was added to a spin column in a collection
tube and centrifuged at 1000 x g for 1minute to remove the liquid from the beads
and then washed twice with 200 µL of PBS. The columns were tapped on a
piece of paper towel to remove excess liquid and the bottom plug was inserted.
100 µL of antibody solution in PBS was added to the beads (specific amounts
used indicated in Table 3.1) and incubated with agitation at room temperature for
60 minutes. After incubation, the plug was removed from the spin column; the
liquid was removed by centrifugation (as above) and washed 1 x 100 µL PBS and
2 x 300 µL PBS. The crosslinking solution was prepared by adding 38.5 µL of
water to the spin columns followed by 2.5 µL of 20X PBS and 9 µL of 2.5 M DSS
in DMSO. The solution was then incubated for 60 minutes at room temperature
with agitation then centrifuged to remove the crosslinking solution (as above).
The beads were then washed 1 x 50 µL of elution buffer (primary amine solution;
pH 2.8) and 2 x 100 µL of elution buffer to remove unbound antibody. The beads
were then washed 2 x 200 µL of IP Lysis /wash buffer (25 mM Tris, 15 mM
sodium chloride, 1 mM EDTA, 1% NP-40 or Igepal, 5% glycerol; pH 7.4). Beads
were then either used immediately or stored in IP Lysis/Wash buffer (200 µL) for
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up to 5 days or for longer in PBS (200 µL) with 0.02% sodium azide. When
stored in PBS, beads were washed 2 x 200 µL of IP lysis/wash buffer prior to
use.

Table 3.1. HDAC Antibody Solutions for Conjugated Protein A Beads.
HDAC
Antibody
1
2
3
4
5
6
7
8
10
11

Volume
used (µL)
1
1
1
10
10
50
5
12
20
20

Amount Volume 20X
used (µg)
PBS (µL)
10.7
5
12.4
5
13.3
5
12.0
5
10.0
5
10.0
5
10.0
5
10.8
5
15.4
5
22
5

Volume
water (µL)
94
94
94
85
85
45
85
83
75
75

Source of antibody
(product number)
Sigma (H3284)
Sigma (H3159)
Sigma (H3034)
Sigma (H9411)
Sigma (H9663)
SCBT (sc-11420)
SCBT (sc-11421)
Sigma (H8038)
Sigma (H3413)
Sigma (H4539)

3.3.8 Co-Immunoprecipitations (IPs) of HDAC proteins from HeLa lysates
Immunoprecipitations were generally done on a scale to load onto 4 gels.
For a typical experiment HeLa lysates were precleared by adding 2 mg (0.5 mg
per gel lane) of total protein per HDAC IP to 20 µL of suspended Protein A
agarose beads and rotated at 4 °C for at least 60 minutes (for 10 HDAC IPs and
control, 22 mg of HeLa lysates was precleared with 220 µL suspended beads).
The precleared lysates were then separated from the agarose beads by
centifugation for 1 minute at 1000 x g, divided into 10 equal volumes, and
aliquoted into the plugged spin columns containing individual HDAC antibodies
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conjugated to Protein A beads (described in section 3.3.5). Spin columns were
filled to a total volume of 300 µL with the pre-cleared lysates diluted in IP
lysis/wash buffer and incubated overnight at 4 °C with rotation to allow protein
binding to antibodies. The following day, the lysates were removed by
centrifugation (1 minute, 1000 x g) and the beads were washed 3 x 200 µL of IP
lysis/wash buffer, and 1 x 100 µL conditioning buffer (Pierce Kit 26147, neutral
pH buffer), centrifuging to remove liquid after each wash. The antigen was then
eluted from the beads with 10 µL of elution buffer (Pierce Kit 26147, primary
amine, pH 2.8) added to the spin columns and collected (1 minute at 1000 x g)
into clean 1.5 mL epitubes containing 2.5 µL of 1 M Tris (pH 9.5 to neutralize the
acidic elution buffer). An additional 30 µL of elution buffer was added to each
spin column and incubated at room temperature for 5 minutes, then collected (1
minute a 1000 x g) into the same epitube as the first elution.

Antibody resins

were immediately washed 2 x 100 µL of PBS to restore the proper pH, and stored
in 200 µL or IP lysis/wash buffer or PBS with 0.02% sodium azide (as described
in previous section); the antibody resins could be reused several times over the
course of 2 weeks. The antigen elution solution was then incubated with 5X SDS
loading buffer (11 µL) and heated to 95 °C for more than 1 minute. The samples
were then loaded onto SDS-PAGE gels (as described below); 13 µL of sample
was loaded into each lane on the gel. Lysate control lanes were prepared by
combining 40 µL of lysates (section 3.3.1) with 10 µL of SDS loading buffer and
heating to 95 °C for 1 minute; 12.5 µL of this solution was loaded onto each gel.
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3.3.9 SDS-PAGE Electrophoresis
Protein samples from NeutrAvidin pull-down experiments and IPs
(sections 3.3.2, 3.3.4 and 3.3.6) were separated by sodium dodecyl sulfate
(SDS)-PAGE electrophoresis prior to western blot analysis. Gels were prepared
so that the separating layer contained a final concentration of 10% 37:1
acrylamide/bisacrylamide (Acros catalog number 330225000) by combining (per
gel) 1 mL of 4X Tris/SDS buffer (0.4% SDS, 1.5 M Tris, 0.24 M HCl; pH 8.8), 1.96
mL of water, 1 mL of 40% 37:1 acrylamide/bisacrylamide, 40 µL of 10%
ammonium persulfate, and 2 µL of N,N,Nʼ,Nʼ-tetramethylethylenediamine (Acros
catalog number 138450500).105 The gel mixture was mixed thoroughly, poured
(around 3 mL) immediately into a BioRad mini-Protean tetra cell casting module
and covered with methanol for polymerization.

The stacking layer was then

prepared by mixing 500 µL of 4X Tris/SDS buffer (as above, pH adjusted to 6.8),
1.24 mL of water, 250 µL of 40% 37:1 acrylamide/bisacrylamide, 10 µL of 10%
ammonium persulfate and 1 µL of tetramethylethylenediamine (per gel). The
methanol was removed from the polymerized separating layer, and the stacking
layer was added followed by an appropriate comb. Once the staking layer was
polymerized, gels were inserted in the BioRad (Protean III) gel apparatus and
filled with SDS running buffer (0.1% SDS, 25 mM Tris, 250 mM glycine; pH 8.3).
Gels were loaded with molecular weight standards and samples using round gelloading tips, and run using constant 200 volts for 60 to 70 minutes.
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3.3.10 Protein Transfer From SDS Gel to PVDF Membrane
SDS-PAGE gels were transferred to a polyvinylidene fluoride (PVDF)
membrane for western blot analysis (Millipore Immobilon-P, 0.45 micron).105 The
membrane was cut to an appropriate size and soaked in methanol to activate the
membrane for protein transfer. The membrane and the gel were assembled
between pieces of filter paper and padding and inserted into the BioRad
chamber.

The chamber was filled with CAPS/Methanol buffer made by

combining 100mL of 10X CAPS buffer (0.1 M CAPS, pH adjusted to 10.5 with 10
M sodium hydroxide) with 100 mL of methanol and filling to 1 L with deionized
water. The protein transfer was performed in the BioRad chamber for 60 to 90
minutes at constant 90 volts, with an ice pack in the chamber to prevent
overheating. After protein transfer was complete the membrane was air dried to
ensure protein binding to the membrane, and then soaked in methanol before
western blot analysis.

3.3.11 Western Blot Analysis
PVDF membranes were blocked 8 hours to overnight using low fat dry
milk (10%) in PBS with Tween-20 (PBST, 0.1 % Tween-20). After blocking was
complete the membranes were washed 3 x 5 minutes with fresh PBST to remove
any unbound milk protein. The primary antibody solutions (10% low fat dry milk
in PBST containing 0.002% sodium azide as a preservative) varied in antibody
concentration and incubation time for each individual protein; Table 3.2
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summarizes the conditions used for primary anti-HDAC antibodies in western
blotting. After incubation with the primary antibody, membranes were washed for
3 x 5 minutes with PBST to remove unbound antibody. The membranes were
then coated with a secondary anti-rabbit antibody with a fluorescent label for
visualization for 60-90 minutes (PBST solution containing 10% low fat dry milk).
Either DyLight 649 (1:3000, Pierce catalog number 35565) or DyLight 649 light
chain specific (1:2500, Jackson ImmunoResearch catalog number 211-492-171)
secondary antibodies were used. The membranes were washed 3 x 5 minutes
with fresh PBST to remove any excess antibody, followed by 1 x 5 minutes of
distilled water. Western blots were visualized using a Typhoon 9210 variable
mode imager (Amersham Biosciences) measuring fluorescence at 670 nm.

Table 3.2. Antibody Solutions for Western Blotting. (For manufacturer
and product number see table 3.1).
HDAC Antibody
1
2
3
4
5
6
7
8
10
11

Dilution
1:10,000
1:10,000
1:1000
1:250
1:200
1:100
1:100
1:100
1:100
1:100

Incubation time
1 hour
1 hour
1 hour
1 hour
Overnight
Overnight
Overnight
Overnight
Overnight
Overnight
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3.3.12 ELISA Plate Assay
The ELISA based plate assay was performed using Pierce Reacti-Bind
secondary goat anti-rabbit IgG coated plates (catalog number 15135).

Clear

plates were used for the colorimetric assay in combination with Pierce 1-Step
Ultra TMB-ELISA horseradish peroxidase (HRP) substrate following the
manufacturerʼs instructions (catalog number 34028). Prior to use, wells were
washed three times with wash buffer (Tris-buffered Saline (TBS, 50 mM Tris-HCl,
150 mM sodium chloride, pH 7.4) containing 0.05 % Tween-20 and 0.1% bovine
serum albumin (BSA)).

Wells were washed using a squirt bottle to fill to

approximately 200 µL, and emptied by inversion. Wells were coated first with
primary antibody solution (100 µL of 1 ng/mL) for 1 hour at room temperature
with rocking. For the anti-HDAC1 (Sigma H3284) antibody, a coating solution
was made by diluting a solution of 1 µg/mL anti-HDAC1 in water (1:1000) into a
dilution buffer (wash buffer containing 3% BSA) to give a final antibody
concentration of 1 ng/mL. Control wells containing no antibody were coated with
dilution buffer during this period. After the hour incubation period, the plate was
emptied by inversion and washed 3 times with wash buffer (as above), then
washed 1 additional time with 200 µL of wash buffer with 5 minutes of rocking
before the plate was emptied and allowed to drain on paper towel. The dried
plates were then coated with the lysate solution and/or SAHA-biotin CID and/or
competitive HDACi. The lysate solution was prepared by diluting HeLa lysates
(usually 5-8 mg/mL) into dilution buffer to a final concentration of 100 µg/mL. 98
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µL of the lysates solution was added to each well. Control wells containing no
lysates were coated with dilution buffer alone. For competitive HDACi treated
wells, 1 µL of 100X solution of SAHA in DMSO was added immediately to the
lysate solution, while 1 µL of DMSO alone was added to the other wells. The
plate was incubated at room temperature with rocking for 10 minutes to allow the
competitive HDACi (SAHA) a binding advantage, after which time 1µL of 100X
SAHA-biotin CID (1 mM to give final concentration of 10 µM) was added; 1 µL of
DMSO was added to control wells. The plate was incubated for an additional 50
mintues, then washed with wash buffer (3 x 200 µL) and then with wash buffer
(200 µL) for 5 minutes with shaking (as above). Pierce Ultra-Sensitive ABC
Peroxidase staining reagent (catalog number 32050) was prepared 30 minutes in
advance by combining 27 µL of reagent A (avidin) and 27 µL of reagent B
(biotinylated peroxidase) in 3 mL of PBS buffer, mixing thoroughly before letting
stand at room temperature to allow the avidin complex to equilibrate. This ABC
reagent (100 µL) was added to each well, and incubated at room temperature for
30 minutes with rocking. The plate was then emptied by inversion and washed
as above.

Finally, room temperature Pierce 1-Step Ultra TMB-ELISA reagent

(catalog number 34028, 100 µL) was added to the plate and incubated until the
positive control reached an absorbance at OD620 around 0.20-0.25. The reaction
was quenched by adding 2M sulfuric acid (100 µL) to all wells and final
absorbance readings were taken at OD450. Plates with unused wells were dried
thoroughly and stored with desiccation at 4 °C.
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APPENDIX A
A.1 Suberic Anhydride (3).
A.1.1

1

H NMR
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A.1.2

13

C NMR

132
A.1.3 IR

133
A.1.4 HRMS
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A.2
A.2.1

8-(benzyloxyamino)-8-oxooctanoic acid (8).
1

H NMR
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A.2.2

13

C NMR

136
A.2.3 IR

137
A.2.4 HRMS
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A.3 2-(4-(8-(benzyloxyamino)-8-oxooctanamido)phenyl)acetic acid (11).
A.3.1

1

H NMR
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A.3.2

13

C NMR

140
A.3.3 IR

141
A.3.4 MS
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A.4 SAHA fragment (20).
A.4.1

1

H NMR
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A.5 Estrone Oxime (14).
A.5.1

1

H NMR

144
A.5.2

13

C NMR

145
A.5.3 IR

146
A.5.4 HRMS
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A.6 2.1 tert-butyl 4-aminobenzylcarbamate (26).
A.6.1

1

H NMR

148
A.6.2

13

C NMR

149
A.6.3 IR

150
A.6.4 HRMS
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A.7 8-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)amino)-8oxooctanoic acid (29).
A.7.1

1

H NMR

152
A.7.2

13

C NMR

153
A.7.3 IR

154
A.7.4 MS

155
A.8 tert-butyl 4-aminophenethylcarbamate (32).
A.8.1

1

H NMR

156
A.8.2

13

C NMR

157
A.8.3 IR

158
A.8.4 MS

159
A.9 8-((4-(2-((tert-butoxycarbonyl)amino)ethyl)phenyl)amino)-8oxooctanoic acid (33).
A.9.1

1

H NMR

160
A.9.2

13

C NMR

161
A.9.3 IR

162
A.9.4 MS

EMILY AUBY
Boc25A
LCT2008-07b.pro 2010-cif.spl

100

0

100

380

375.2314

370

393.2390

394.2422
395.2448

400

394.2437

393.2388

390

412.2713

415.2209

417.2268

416.2241

420

416.2242

415.2212

410

410.2664

2011_0628_1991 (0.019) Is (0.02,0.01) C21H32N2O5H

0

100

360

2011_0628_1991 13 (0.284) Cm (11:18-1:6x2.000)

0

411.2686

410.2655

2011_0628_1991 (0.019) Is (0.02,0.01) C21H32N2O5NH4

100

2011_0628_1991 (0.019) Is (0.02,0.01) C21H32N2O5Na

0

%
%
%
%

440

480

490

500

494.3580
492.3452
495.3589

m/z

1: TOF MS ES+
1.09e3

1: TOF MS ES+
7.74e12

1: TOF MS ES+
7.74e12

1: TOF MS ES+
7.71e12

28-Jun-2011LCT Premier15:46:50

470

466.3206

460

451.2864

450

439.3008

438.2972

431.1929

430

163
A.10 9H-fluoren-9-yl)methyl 4-aminophenethylcarbamate (37).
A.10.1 1H NMR

164
A.10.2 13C NMR

165
A.10.3 IR

166
A.10.4 MS

167
A.11 6-(bromomethyl)pteridine-2,4-diamine (47).
A.11.1 1H NMR

168
A.11.2 13C NMR

169
A.11.3 IR

170
A.11.4 MS

171
A.12 MTX fragment (42).
A.12.1 1H NMR

172
A.12.2 13C NMR

173
A.12.3 IR

174
A.12.4 MS

175
A.13 SAHA-biotin CID A (22).
A.13.1 Crude HPLC
996 at 254.00 - PDA 210.0 to 400.0 nm at 1.2 nm
996 at 220.00 - PDA 210.0 to 400.0 nm at 1.2 nm

2.80
2.60
2.40
2.20
2.00
1.80

AU

1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00
Minutes

20.00

22.00

24.00

26.00

28.00

30.00

32.00

34.00

A.13.2 HPLC Re-inject
1.40

996 at 254.00 - PDA 210.0 to 400.0 nm at 1.2 nm
996 at 220.00 - PDA 210.0 to 400.0 nm at 1.2 nm

1.30
1.20
1.10
1.00
0.90

AU

0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00
Minutes

20.00

22.00

24.00

26.00

28.00

30.00

32.00

34.00
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A.14

SAHA-biotin CID B (36).

A.14.1 Crude HPLC Method A
996 at 254.00 - PDA 210.0 to 400.0 nm at 1.2 nm
996 at 220.00 - PDA 210.0 to 400.0 nm at 1.2 nm

3.40
3.20
3.00
2.80
2.60
2.40
2.20
2.00

AU

1.80
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
-0.20
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

A.14.2 Crude HPLC Method B

Red line = 214 nm; black line = 254 nm.

18.00
Minutes

20.00

22.00

24.00

26.00

28.00

30.00

32.00

34.00

177
A.14.3 HPLC Re-inject Method B

Black line = 214 nm; red line = 254 nm.

A.14.4 HRMS
Elemental Composition Report

Page 1

Single Mass Analysis
Tolerance = 5.0 PPM / DBE: min = -1.5, max = 150.0
Element prediction: Off
Number of isotope peaks used for i-FIT = 6
Monoisotopic Mass, Even Electron Ions
2699 formula(e) evaluated with 12 results within limits (up to 50 closest results for each mass)
Elements Used:

C: 0-100

H: 0-1000

N: 0-8

O: 0-9

23Na: 0-1

S: 0-1

EMILY AUBY
SAHA B
LCT2008-07b.pro 2010-cif.spl
28-Jun-2011LCT Premier16:04:53
1: TOF MS ES+
2.34e+003

2011_0628_1992 13 (0.283) Cm (10:18-1:6x2.000)
100
%
0

679.3488

701.3312
681.3505

680.0

682.5

686.3241
685.0

Minimum:
Maximum:

687.5

696.4297
690.0

692.5

695.0

5.0

5.0

-1.5
150.0

697.5

700.0

702.3359

702.5

705.0

717.3031
707.5

Mass

Calc. Mass

mDa

PPM

DBE

i-FIT

i-FIT (Norm) Formula

679.3488

679.3489
679.3485
679.3496
679.3472
679.3505
679.3471
679.3509
679.3465
679.3512
679.3519
679.3457
679.3455

-0.1
0.3
-0.8
1.6
-1.7
1.7
-2.1
2.3
-2.4
-3.1
3.1
3.3

-0.1
0.4
-1.2
2.4
-2.5
2.5
-3.1
3.4
-3.5
-4.6
4.6
4.9

10.5
21.5
19.5
16.5
11.5
23.5
24.5
7.5
20.5
16.5
18.5
15.5

17.2
18.3
18.5
18.2
18.3
21.1
19.7
18.5
20.2
19.6
22.6
19.0

1.1
2.2
2.4
2.1
2.2
5.0
3.6
2.4
4.2
3.5
6.6
2.9

C32
C39
C40
C38
C35
C44
C41
C30
C43
C36
C43
C35

H51
H44
H47
H48
H52
H47
H43
H52
H48
H48
H51
H47

N6
N8
N4
N4
N4
N4
N8
N6
N2
N8
O5
N6

710.0

712.5

O8 S
O2 23Na
O6
O6 23Na
O6 23Na
O S
O2
O8 23Na
O4 23Na
O2 23Na
S
O8

S
S
S

715.0

717.5

723.3144 724.4038
720.0

722.5

725.0

m/z

178
A.15

SAHA-MTX CID (41).

A.15.1 Crude HPLC

Black line = 214 nm; blue line = 254 nm; red line = 336 nm.
A.15.2 HPLC Re-inject

Black line = 214 nm; blue line = 254 nm; red line = 336 nm
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A.15.3 HRMS
Elemental Composition Report

Page 1

Single Mass Analysis
Tolerance = 5.0 PPM / DBE: min = -1.5, max = 150.0
Element prediction: Off
Number of isotope peaks used for i-FIT = 6
Monoisotopic Mass, Even Electron Ions
3435 formula(e) evaluated with 16 results within limits (up to 50 closest results for each mass)
Elements Used:

C: 0-100

H: 0-1000

N: 0-15

O: 0-10

23Na: 0-1

EMILY AUBY
SAHA M
LCT2008-07b.pro 2010-cif.spl
29-Jun-2011LCT Premier10:17:41
1: TOF MS ES+
1.08e+004

2011_0629_1994 16 (0.318) Cm (14:18-1:8x2.000)
100
%
0

206.0783
200

456.2080

309.7941
300

Minimum:
Maximum:

551.3553
400

500

696.4266

600

700

5.0

5.0

-1.5
150.0

889.4299
891.4373 987.5152
874.4198
800

900

1000

1334.1405
1100

Mass

Calc. Mass

mDa

PPM

DBE

i-FIT

i-FIT (Norm) Formula

889.4299

889.4297
889.4321
889.4337
889.4262
889.4265
889.4278
889.4289
889.4302
889.4292
889.4305
889.4316
889.4318
889.4329
889.4342
889.4257
889.4270

0.2
-2.2
-3.8
3.7
3.4
2.1
1.0
-0.3
0.7
-0.6
-1.7
-1.9
-3.0
-4.3
4.2
2.9

0.2
-2.5
-4.3
4.2
3.8
2.4
1.1
-0.3
0.8
-0.7
-1.9
-2.1
-3.4
-4.8
4.7
3.3

17.5
20.5
21.5
29.5
25.5
30.5
28.5
33.5
24.5
29.5
27.5
34.5
32.5
37.5
36.5
41.5

32.5
33.5
34.9
36.4
36.4
34.7
34.7
34.0
34.8
34.3
35.6
34.5
36.5
37.6
39.0
37.4

0.9
1.9
3.3
4.8
4.8
3.1
3.1
2.4
3.2
2.7
4.0
2.9
4.9
6.0
7.4
5.8

C40
C42
C45
C49
C51
C52
C53
C54
C55
C56
C57
C57
C58
C59
C64
C65

H58
H57
H58
H53
H58
H54
H57
H53
H62
H58
H61
H54
H57
H53
H57
H53

1200

N12
N12
N10
N12
N6
N10
N6
N10
O9
N4
O9
N8
N4
N8
O4
N4

1300

O10 23Na
O10
O8 23Na
O5
O7 23Na
O3 23Na
O7
O3
23Na
O5 23Na
O 23Na
O5
O

1778.8613
m/z
1400

1500

1600

1700
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B APPENDIX B
B.1 Yeast Three Hybrid Raw Data
B.1.1 SAHA-biotin Y3H

SAHA-biotin trial 1

1

2

3

4

5

6

OD600

0.9250

0.8123

0.7196

0.9322

0.8008

0.7974

OD420

0.0528

0.0705

2.9252

0.0524

0.0767

2.9716

OD420/(OD600*0.25mL*20 min)

0.0114

0.0174

0.8130

0.0112

0.0192

0.7453

/lane 1 no zymo (0.0114) (fold)

1.0000

1.5205

71.215

0.9848

1.6779

65.286

OD600

0.8342

0.6460

0.6033

0.8426

0.6432

0.5957

OD420

0.0586

0.0565

2.8726

0.0533

0.0662

2.9663

OD420/(OD600*0.25mL*20 min)

0.0140

0.0175

0.9523

0.0127

0.0206

0.9959

/lane 1 no zymo (0.0114) (fold)

1.2307

1.5322

83.416

1.1082

1.8031

87.236

1

2

3

4

5

6

OD600

0.7073

0.5063

0.2348

0.6531

0.4847

0.2664

OD420

0.0535

0.0559

2.3921

0.0541

0.0601

2.9982

OD420/(OD600*0.25mL*30 min)

0.0101

0.0147

1.3584

0.0110

0.0165

1.5006

/lane 1 no zymo (0.0101) (fold)

1.0002

1.4599

134.71

1.0953

1.6396

148.82

OD600

0.6525

0.4523

0.2528

0.7143

0.4136

0.2517

OD420

0.0514

0.0598

2.7637

0.0517

0.0624

2.9976

OD420/(OD600*0.25mL*30 min)

0.0105

0.0176

1.4576

0.0097

0.0201

1.5879

/lane 1 no zymo (0.0101) (fold)

1.0416

1.7482

144.56

0.9571

1.9949

157.48

Average 2 trials No Zymo

1.0001

1.4902

102.96

1.0400

1.6588

107.05

Average 2 trials With Zymo

1.1361

1.6402

113.99

1.0326

1.8990

122.36

pSH 18-34

+

+

+

+

+

+

pSA1 SA T7-B42

-

+

-

-

+

-

pSH 17-4

-

-

+

-

-

+

SAHA-biotin B (100 uM)

-

-

-

+

+

+

No Zymo

With Zymo

SAHA-biotin trial 2
No Zymo

With Zymo
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B.1.2 SAHA-MTX Y3H

SAHA-MTX trial 1

1

2

3

4

5

6

7

8

OD600

0.7409

0.5170

0.6580

0.7428

0.7613

0.4880

0.6342

0.7339

OD420
OD420/(OD600*0.25mL
*60min)
/lane 1 no Zymo
(0.0058) (fold)

0.0641

0.0715

0.0711

1.8278

0.0668

0.0660

0.0755

1.6342

0.0058

0.0092

0.0072

0.1640

0.0058

0.0090

0.0079

0.1484

1.0000

1.5985

1.2490

28.44

1.0142

1.5632

1.3760

25.738

OD600

0.5184

0.4283

0.4821

0.5436

0.5897

0.4382

0.8289

0.5900

OD420
OD420/(OD600*0.25mL
*60min)
/lane 1 no Zymo
(0.0058) (fold)

0.0786

0.0660

0.0648

1.5753

0.0698

0.0664

0.0727

1.9839

0.0101

0.0103

0.0090

0.1932

0.0079

0.0101

0.0058

0.2242

1.7525

1.7811

1.5536

33.495

1.3681

1.7514

1.0138

38.866

1

2

3

4

5

6

7

8

OD600

0.6731

0.3850

0.4632

0.5497

0.5326

0.4031

0.5872

0.4676

OD420
OD420/(OD600*0.25mL
*50min)
/lane 1 no Zymo
(0.0063) (fold)

0.0534

0.0561

0.0532

1.8484

0.0525

0.0599

0.0559

0.9832

0.0063

0.0117

0.0092

0.2690

0.0079

0.0119

0.0076

0.1682

1.0000

1.8367

1.4477

42.385

1.2425

1.8731

1.2000

26.504

OD600

0.4970

0.3129

0.4834

0.4385

0.4337

0.2811

0.4430

0.4179

OD420
OD420/(OD600*0.25mL
*50min)
/lane 1 no Zymo
(0.0063) (fold)

0.0519

0.0534

0.0520

1.0696

0.0503

0.0531

0.0574

1.7111

0.0084

0.0137

0.0086

0.1951

0.0093

0.0151

0.0104

0.3276

1.3163

2.1512

1.3559

30.746

1.4619

2.3811

1.6332

51.611

1.0000

1.7176

1.3483

35.413

1.1283

1.7182

1.2880

26.121

1.5344

1.9662

1.4548

32.121

1.4150

2.0663

1.3235

45.238

pMW 112

+

+

+

+

+

+

+

+

pSA1 HDAC1-B42

-

+

-

-

-

+

-

-

pSA1 RPD3-B42
p424 HDAC1-VP16LexA

-

-

+

-

-

-

+

-

-

-

-

+

-

-

-

+

SAHA-MTX (100 μM)

-

-

-

-

+

+

+

+

No Zymo

With Zymo

SAHA-MTX trial 2
No Zymo

With Zymo

Average 2 trials No
Zymo
Average 2 trials With
Zymo
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B.2 Duplicate Western Analyses
B.2.1 HDAC2 Co-IPs

A

B
anti-HDAC1
anti-HDAC2

1a 2a 2b 2c 2d 2e 3a 4a 4b 4c 4d 4e

1a 2a 2b 2c 2d 3a 4a 4b 4c 4d

Figure B.1. Western Blot Analysis of HDAC1 and HDAC2 With
Varying Wash Conditions. Western blot analysis (antibodies indicated in
middle of figure) of HDAC1 and HDAC2. Lane 1: HeLa lysates (10%
loading); Lanes 2: HDAD2 IP; Lane 3: control no SAHA-biotin CID with
NeutrAvidin beads; Lanes 4: SAHA-biotin (1 μM) pre-incubated with
NeautrAvidin beads. Washing conditions 3 x 1mL JLB varying [NaCl] a)
150mM; b) 500 mM; c) 1 M; d) 1.5 M; e) 2 M. Panel A) performed in the
absence of lysate pre-clearing with protein A agarose (lanes1-2) or
NeutrAvidin resin (lanes 3-4); panel B) lysates pre-cleared with protein A
(lanes1-2) or NeutrAvidin resin (lanes 3-4) agarose prior to experiment.
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B.2.2 HDAC Co-IPs
anti-HDAC1
anti-HDAC2
anti-HDAC3
anti-HDAC4
anti-HDAC5
anti-HDAC6
anti-HDAC7
anti-HDAC8
anti-HDAC10
anti-HDAC11
Lys C 1 2 3 4 5 6 7 8 10
11
Figure B.2. HDAC Co-IPs from HeLa Lysates. Individual HDACs (lanes
across bottom of gel) were immunoprecipitated from HeLa lysates,
separated by SDS-PAGE, followed by western blot analysis with
antibodies indicated to the right (Lys = 10% of input, C = Control, no
antibody). IP for HDAC 5 was unsuccessful, as were IPs for HDAC8 and
HDAC11.
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B.3 Raw Data For HDAC-Dependent ELISA

C Table B.1. HDAC1-Dependent ELISA With Varying Concentration of
SAHA-Biotin CID B (36). HeLa lysates were treated with varying
concentration of SAHA-biotin CID B (36) (µM concentrations listed below
bars) and absorbance of HRP substrate, TMB, was measured at 450 nm.
Results are the average of two simultaneous trials.
[SAHA-biotin B (36)] (μM) HeLa Lysate (ug/mL)
5.0
0
0.0
100
0.01
100
0.1
100
1.0
100
2.5
100
5.0
100
10
100
20
100

OD450 Trial 1
0.1303
0.1318
0.1259
0.1260
0.1656
0.2160
0.2682
0.4797
0.9920

OD450 Trial 2
0.1276
0.1396
0.1376
0.1441
0.1680
0.2939
0.3419
0.5533
1.0685

Average OD450
0.1290
0.1357
0.1318
0.1351
0.1668
0.2550
0.3051
0.5165
1.0303

Table B.2. HDAC1-Dependent ELISA With Varying Concentration of
Competitive SAHA. HeLa lysates were treated with 10 µM SAHA-biotin
CID B (36) in the presence of varying concentration of SAHA (µM
concentrations listed in table below below bars) and absorbance of HRP
substrate, TMB, was measured at 450 nm.
[SAHA-biotin B (36)] (µM)
10
0
10
10
10
10
10
10

[SAHA] (μM)
0
0
0
10
100
200
500
1000

HeLa Lysate (ug/mL)
0
100
100
100
100
100
100
100

OD450 Trial 1
0.2452
0.0788
1.7475
1.6334
0.9346
0.7995
0.2690
0.1521
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ABSTRACT
DEVELOPMENT OF A CHEMICAL INDUCER OF DIMERIZATION FOR
SCREENING COMPETITIVE HISTONE DEACTELYASE INHIBITORS
by
EMILY LYNN AUBIE
August 2011
Advisor: Dr. Mary Kay H. Pflum
Major: Chemistry (Organic)
Degree: Doctor of Philosophy
Histone Deacetylase (HDAC) proteins are transcriptional regulators that
affect histone proteins, which are involved in packaging of DNA into
chromosomes. HDACs have been linked to the proliferation of cancer through
their role in transcriptional regulation. Due to these findings, HDAC inhibitors
have been explored as anti-cancer agents. Several HDAC inhibitors are currently
in various stages of clinical trials, and the inhibitor suberoyl anilide hydroxamic
acid (SAHA) has been FDA approved for treatment of cutaneous T-Cell
lymphoma.

Currently, most of the known HDAC inhibitors are non-selective,

which causes non-specific binding to the active sites of all HDAC isoforms,
including those not involved in cancer. To date, screening for HDAC inhibitors
has been done using an in vitro fluorescence-screening assay, which is unable to
test for selectivity.

Alternatively, HDAC inhibitors are screened against

commercially produced proteins, which is very time consuming and can be
prohibitively expensive. To improve the screening methods for HDAC inhibitors,

205
we are developing an assay to screen HDAC inhibitors against individual
isoforms in a high-throughput assay. The assay has been developed using a
competitive bifunctional small molecule based on SAHA to test for inhibitor
binding.
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